WO2012028673A1 - Organogenèse spontanée dans des plantes - Google Patents

Organogenèse spontanée dans des plantes Download PDF

Info

Publication number
WO2012028673A1
WO2012028673A1 PCT/EP2011/065070 EP2011065070W WO2012028673A1 WO 2012028673 A1 WO2012028673 A1 WO 2012028673A1 EP 2011065070 W EP2011065070 W EP 2011065070W WO 2012028673 A1 WO2012028673 A1 WO 2012028673A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclops
amino acid
seq
plant
nucleotide sequence
Prior art date
Application number
PCT/EP2011/065070
Other languages
English (en)
Inventor
Martin Parniske
Sylvia Singh
Original Assignee
Ludwig-Maximilians-Universitaet Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10175012A external-priority patent/EP2426204A1/fr
Application filed by Ludwig-Maximilians-Universitaet Muenchen filed Critical Ludwig-Maximilians-Universitaet Muenchen
Publication of WO2012028673A1 publication Critical patent/WO2012028673A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants

Definitions

  • the present invention provides a plant comprising a nucleotide sequence of a (mutant) CYCLOPS gene, wherein said nucleotide sequence comprises at a first position corresponding to position 148-150 of the nucleotide sequence shown in SEQ ID No: 1 and/or at a second position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid mimicking the effects of phosphorylation.
  • plants which comprise a CYCLOPS protein having at a first position corresponding to position 50 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 and/or at a second position corresponding to position 154 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation.
  • the plants of the present invention are capable of developing root nodules, preferably spontaneously developing nodules, preferably in the absence of rhizobia and/or rhizobial signal molecules.
  • Plants benefit from interactions with symbiotic bacteria and fungi, to improve their phosphate and nitrogen supply, and it is those interactions in particular that hold the promise of becoming an integral part of a more sustainable agriculture.
  • RNS root nodule symbiosis
  • the primary source of biological nitrogen fixation are Gram negative rhizobia and the Gram positive actinobacterium Frankia spp, which are a small group of prokaryotes that produce nitrogenases, and form endosymbiotic associations with plants conferring the ability to fix nitrogen. Although many plants can associate with nitrogen-fixing bacteria, only a few plants form endosymbiotic associations with rhizobia or Frankia, which are unique in that most of the nitrogen is transferred to and assimilated by the host plant.
  • the Leguminosae plant family which includes soybean, bean, pea, peanut, chickpea, cowpea, lentil, pigeonpea, alfalfa and clover, are the most agronomically important members of this small group of nitrogen-fixing plants. Biological nitrogen fixation via the endosymbiotic association reduces the need for expensive nitrogen fertilizers in legume crops and is an important feature of sustainable agriculture. Legumes can also utilize nitrogen available in the soil, such that when levels of soil nitrate are high, nodule formation is suppressed and the plant shifts from nitrogen metabolism to growth on nitrate.
  • legume plants can establish endosymbiotic interactions with nitrogen- fixing rhizobia and phosphate-delivering arbuscular mycorrhiza (AM) fungi.
  • A arbuscular mycorrhiza
  • RNS root nodule symbiosis
  • Is plant membrane-delimited infection threads
  • AM fungal hyphae are guided through epidermal and cortical cells toward the inner cortex, where arbuscules, highly branched intracellular symbiotic structures, are formed.
  • Rhizobia Intracellular infection by rhizobia and AM fungi is preceded by an exchange of specific signaling molecules.
  • Rhizobia produce lipochito-oligosaccharides (Nod factors) that activate host plant responses including root hair deformation, and preinfection thread formation, which are structures that determine the path of IT growth through the root, and initiation of cortical cell division.
  • Nod factors lipochito-oligosaccharides
  • One of the earliest plant responses to stimulation by Nod factors is calcium-spiking, which consists of perinuclear oscillations of calcium concentration in root cells.
  • rhizobium-legume symbiosis involves the interaction of a set of plant and bacterial genes in a complex process leading to the initiation and development of root nodules.
  • Organogenesis of nodules is triggered by the rhizobial microsymbiont, but the legume host plant encodes the developmental program responsible for building the nodule tissues and for regulating the process.
  • Lipo-chitin-oligosaccharides (Nod-factors) synthesized and secreted by Rhizobia are major signal molecules that trigger the process of organogenesis including nodule formation.
  • the major Nod-factor secreted by the Mesorhizobium loti microsymbiont of Lotus is a pentameric N-acetylglucosamine carrying a cis-vaccenic acid and a carbamoyl group at the non-reducing terminal residue together with a 4-O-acetylfucose at the reducing terminal residue.
  • Perception of Nod-factor in Lotus is mediated by NFR1 and NFR5 receptor kinases (Radutoiu et al. (2003), Nature 425, 585-592; Madsen et al.
  • the predicted protein products of these 'common symbiosis genes' include a receptor kinase that is also required for actinorhiza symbiosis and has been implicated in the evolution of nodulation (Markmann et al. (2008), PLoS Biol. 6, e68). Together with nuclear envelope localized ion channels (Charpentier et al. (2009), Plant Cell 20, 3467-3479) and components of the NUP84 sub-complex of the nuclear pore (Kanamori et al. (2006), Proc Natl Acad Sci USA 103, 359-364; Saito et al.
  • CCaMK is a calcium and calmodulin dependent protein kinase that is believed to decode calcium-spiking signatures that are induced within minutes upon symbiotic stimulation of root cells (Tirichine et al., (2006), cited herein). CCaMK interacts with and phosphorylates CYCLOPS (Yano et al., 2008, cited herein).
  • CCaMK forms a preassembled complex with CYCLOPS in the nucleus, as interaction occurs in the absence of a calcium stimulus, cyclops mutants are defective AM and RNS, but show a wildtype-like calcium spiking response (Yano et al., (2008), cited herein).
  • the mutant name is derived from its particular phenotype characterized by a root hair curl entrapping a bacterial microcolony. At this early stage, progression of infection via an infection thread is blocked.
  • CYCLOPS was shown to interact with CCaMK both in yeast in the Gal4 yeast two-hybrid (Y2H) assay and in planta in Bimolecular Fluorescence Complementation (BiFC) experiments.
  • BIFC is a non-invasive fluorescent-based technique that allows detection of protein-protein interactions in living cells, and furthermore can be used to determine subcellular localization of the interacting proteins, and if it changes over time, without requiring addition of external agents.
  • BiFC is based upon reconstitution of split non- fluorescent GFP variants, primarily YFP, to form a fluorescent fluorophore.
  • CCaMK and CYCLOPS interact in the nucleus of plant cells where they presumably form a pre-assembled complex as interaction is detected in the absence of a calcium stimulus.
  • In vitro kinase assays identified CYCLOPS as phosphorylation substrate of CCaMK.
  • the cyclops mutant phenotype indicates that CYCLOPS is located downstream of CCaMK, as in contrast to cyclops, ccamk mutants do not show a root hair curling response towards rhizobia. Further, upon rhizobial infection, cyclops mutants form small, uninfected nodule primordia, while ccamk loss-of-function mutants do not initiate nodule organogenesis.
  • the present invention addresses this need and thus provides as a solution to the technical problem embodiments pertaining to plants, in particular to land plants capable of symbiosis with arbuscular mycorrhiza such as non-legume plants, that are capable of spontaneous organogenesis, in particular capable of spontaneous root nodule formation, because of the activity of a CYCLOPS protein having (an) amino acid(s) that mimic phosphorylation of (normally) in planta phosphorylated amino acids, thereby providing the structures (root nodules) required by rhizobia to become beneficial for plants in that they fix nitrogen, as well as methods of uses of these plants.
  • CYCLOPS protein having (an) amino acid(s) that mimic phosphorylation of (normally) in planta phosphorylated amino acids, thereby providing the structures (root nodules) required by rhizobia to become beneficial for plants in that they fix nitrogen, as well as methods of uses of these plants.
  • the present invention provides a plant comprising a nucleotide sequence of a (mutant) CYCLOPS gene, wherein said nucleotide sequence comprises at a first position corresponding to position 148-150 of the (wild-type) nucleotide sequence shown in SEQ ID No:1 and/or at a second position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid mimicking the effects of phosphorylation.
  • CYCLOPS contains in total 5 phosphorylation sites. Accordingly, it is a preferred embodiment of the present invention that a nucleotide sequence comprising at a first position corresponding to position 148-150 of the (wild-type) nucleotide sequence shown in SEQ ID No: 1 and/or at a second position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No: 1 , comprises in addition at a further position corresponding to position 40-42 and/or 751-753 and/or 1234-1236 of the nucleotide sequence shown in SEQ ID No: 1 , a codon encoding an amino acid mimicking the effects of phosphorylation.
  • nucleotide sequence comprising at one or more positions corresponding to position(s) 40-42, 148-150, 460-462, 751-753 and/or 1234-1236 of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid mimicking the effects of phosphorylation, is envisaged that shows the same effect (activity) as the CYCLOPS double D mutant. Said activity can be tested as described elsewhere herein.
  • the present invention provides a plant encoding a (mutant) CYCLOPS protein having at a first position corresponding to position 50 of the amino acid sequence of the (wild-type) CYCLOPS protein shown in SEQ ID No:2 and/or at a second position corresponding to position 154 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation.
  • a (mutant) CYCLOPS protein comprises at a first position corresponding to position 50 of the amino acid sequence shown in SEQ ID No:2 and/or at a second position corresponding to position 154 of the amino acid sequence shown in SEQ ID No:2, comprises in addition at a further position corresponding to position 14 and/or 251 and/or 412 of the amino acid sequence shown in SEQ ID No:2, a an amino acid mimicking the effects of phosphorylation.
  • a (mutant) CYCLOPS protein comprising at one or more positions corresponding to position(s) 14, 50, 154, 251 and/or 412 of the amino acid sequence shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation, is envisaged that shows the same effect (activity) as the CYCLOPS double D mutant. Said activity can be tested as described elsewhere herein.
  • the present inventors aimed at a detailed structural and functional characterization of the nuclear CCaMK/CYCLOPS signaling complex by means of genetical, physiological and biochemical approaches.
  • the present inventors were also addressing the interesting specificity and underlying mechanisms leading to distinct responses (e.g. nodule formation in RNS but not during AM) downstream of calcium spiking.
  • CYCLOPS is not involved in nodule organogenesis (see page 148, legend of Figure 5). Indeed, it was previously observed that a constitutively active CCaMK complements a cyclops mutant plant insofar that nodules were formed, it has been found that CYCLOPS plays an important role. Specifically, “activated”, i.e., CYCLOPS having at one or one or more (preferably at two) phosphorylation sites an acidic amino acid (such as "CYCLOPS double D" having an aspartate at a position corresponding to position 50 and 154, respectively, of the amino acid sequence shown in SE ID No:2) rather than a serine residue is capable of forming nodules.
  • activated i.e., CYCLOPS having at one or one or more (preferably at two) phosphorylation sites an acidic amino acid (such as "CYCLOPS double D" having an aspartate at a position corresponding to position 50 and 154, respectively, of the amino acid sequence shown in SE
  • the present inventors' finding may prove instrumental in biotechnological approaches with the aim to provide cultivars with improved nutrition through genetically optimised symbiosis.
  • the common symbiosis genes including CYCLOPS are widespread in angiosperms including major fodder, fruit, vegetable and cereal crops
  • CYCLOPS mutant alleles encoding CYCLOPS mimicking in planta phosphorylation may be one component in a multistep strategy to transfer the root nodule symbiosis to non-legume crop plants.
  • the five identified phosphorylated serine residues were replaced by alanine by site-directed mutagenesis, in order to create un-phosphorylateable residues.
  • the resulting sequenceQuintuple-A" genomic mutant construct equipped with the CYCLOPS promoter and fused to an N-terminal 3xHA-tag was introduced into the cyclops-3 mutant background by hairy root transformation and complementation of AM and RNS was analyzed five weeks post infection (wpi). When compared to the wildtype control, the tillQuintuple-A mutant" did not complement RNS and AM.
  • CYCLOPS S50 and S154 orthologous phosphorylation sites of Interacting Protein of DMI3 (IPD3, the Medicago orthologue of Lotus CYCLOPS (Messinese et al. (2007). Mol Plant Microbe Interact. 8, 912-921) were independently identified in Medicago roots (Grimsrud et al. (2010), Plant Physiol. 152, 19-28), thus confirming these sites to be phosphorylated in vivo.
  • Grimsrud et al. do not describe anything that goes beyond the mere showing of phosphorylated IPD3.
  • the pUB:CYCLOPS-S50DS154D construct was introduced into the ccamk-3 background and the symbiosis phenotype of non-inoculated plants, plants inoculated with AM fungi, or inoculated with M. loti was assessed 5 weeks post infection (wpi). The construct failed to restore infection with AM fungi or M. loti ( Figure 4). Most surprisingly, transformation of CYCLOPS-S50DS154D was sufficient for the spontaneous formation of nodules in the absence of rhizobia ( Figure 4), demonstrating that CYCLOPS double D is upstream of the organogenesis program.
  • mutating CYCLOPS may pave the way to induce nodules - even in non- legume crop plants. If these nodules are colonized by nitrogen-fixing bacteria as symbionts, plants could tremendously benefit and less or even no fertilizer may be required in agriculture.
  • the present invention may prove instrumental in biotechnological approaches with the aim to provide cultivars with improved nutrition through genetically optimised symbiosis. Since the common symbiosis genes including CYCLOPS are widespread in angiosperms including major cereal crops, for example, CYCLOPS double D may be one component in a multistep strategy to transfer the root nodule symbiosis to non- legume crop plants.
  • plant intended to mean a plant at any developmental stage, as well as any part or parts of a plant that may be attached to or separate from a whole intact plant.
  • parts of a plant include, but are not limited to, organs, tissues, and cells of a plant including, plant calli, plant clumps, plant protoplasts and plant cell tissue cultures from which plants can be regenerated.
  • Examples of particular plant parts include a stem, a leaf, a root, an inflorescence, a flower, a floret, a fruit, a pedicle, a peduncle, a stamen, an anther, a stigma, a style, an ovary, a petal, a sepal, a carpel, a root tip, a root cap, a root hair, a leaf hair, a seed hair, a pollen grain, a microspore, an embryos, an ovule, a cotyledon, a hypocotyl, an epicotyl, xylem, phloem, parenchyma, endosperm, a companion cell, a guard cell, and any other known organs, tissues, and cells of a plant. Furthermore, it is recognized that a seed is a plant.
  • Plants of the present invention preferably also include plants, preferably land plants which can be infected by symbiotic arbuscular mycorrhiza (AM) fungi. Also included by the term “plant” are dicotyledones, monocotyledons, gymnosperms, angiosperms including plants of agricultural or pharmaceutical value which are capable to form AM), liverworths, mosses, hornworts, lycophytes, monilophytes, gymnosperms and angiosperms, but plants of the present invention are not limited thereto.
  • AM arbuscular mycorrhiza
  • plants (source material) that are intended to then contain/express a mutant CYCLOPS nucleic acid of the present invention do not have a cyclops, ccamk, Ihk1 or the like (inactivating) mutation, i.e., are inactive as regards these genes.
  • plants (source material) that are intended to then contain/express a mutant CYCLOPS nucleic acid of the present invention do not have a ccamk and/or Ihk1 gain-of-function.
  • non-legume plants including non-legume crop plants.
  • Further preferred plants include all angiosperm plants with nutritional or pharmaceutical vale that form AM, these include among many thousand other plants, important crops such as rice, barley, wheat, oat, rye, maize, sugar cane, poaceae grasses, cucumber, melon, tomato, wine, strawberry, etc.
  • the only limitations may be very few exceptional plant families that have recently lost the ability to form AM, including the Brassicaceae (including rape), the Resedeaceae and the Chenopodiaceae (including sugar beet (Beta vulgaris). But since the mutations responsible for the loss of AM are unknown in most cases, CYCLOPS double D may still work in these plants.
  • Thiese findings suggest a key role of mycorrhizas in the colonization of land by plants and also that almost all land plants have the capability of forming symbiotic mycorrhizas.
  • This analysis also shows that the basal genes required for the root nodule symbioses with rhizobial or Frankia bacteria are widespread in the plant kingdom.
  • Wang et al. show that diverse plants have genes required for forming symbioses with arbuscular mycorrhizas and/or with rhizobia. More specifically, Wang et al. show that mycorrhizal genes were present in the common ancestor of land plants, and that their functions were largely conserved during land plant evolution.
  • the evidence presented here strongly suggests that plant-mycorrhizal fungus symbiosis was one of the key processes that contributed to the origin of land flora.
  • CYCLOPS belongs to the IPD3 proteins (as described in detail herein elsewhere) and that IPD3 is present in almost all land plants and that further genes required for mycorrhizas are also present in these plants (see Table 1 of Wang et al., also shown herein below), it is more than plausible and reasonable to conclude that plants of the present invention when containing and/or expressing a mutant CYCLOPS gene/protein of the present invention have the capability to spontaneously develop nodules, in particular root nodules, thereby providing the structures required for symbiosis with rhizobial bacteria (and for symbiosis with arbuscular mycorrhiza).
  • nucleotide sequence(s) When referred to herein the terms "nucleotide sequence(s)”, “polynucleotide(s)”, “nucleic acid sequence(s)” “nucleic acid(s)”, “nucleic acid molecule” are used interchangeably and refer to nucleotides, either ribonucleotides or deoxyribonucleotides or a combination of both, in a polymeric unbranched form of any length. Nucleic acid sequences include DNA, cDNA, genomic DNA, RNA, synthetic forms and mixed polymers, both sense and antisense strands, or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those skilled in the art.
  • a "gene” when used herein is, so to say, a species of a nucleotide sequence and comprises a coding sequence for a gene (here the CYCLOPS gene) and, optionally a 5'-UTR (containing, for example, expression control elements such as a promoter) and/or 3'-UTR (containing, for example, a termination signal sequence).
  • the gene may be composed of exons and introns or may be free of introns, thus merely composed of exons. It may be composed of DNA, genomic DNA or cDNA.
  • nucleic acid to be expressed is equipped with regulatory elements ensuring transcription and translation in the given host, i.e., elements which are recognized by the transcription and translation machinery of the chosen host.
  • regulatory elements may include, e.g. promoters, terminators, enhancers, targeting signals, ribosome binding sites, etc. and are known in the art and also described herein below.
  • polypeptide or "protein” (both terms are used interchangeably herein) means a peptide, a protein, or a polypeptide which encompasses amino acid chains of a given length, wherein the amino acid residues are linked by covalent peptide bonds.
  • peptidomimetics of such proteins/polypeptides wherein amino acid(s) and/or peptide bond(s) have been replaced by functional analogs are also encompassed by the invention as well as other than the 20 gene-encoded amino acids, such as selenocysteine.
  • Peptides, oligopeptides and proteins may be termed polypeptides.
  • the terms polypeptide and protein are often used interchangeably herein.
  • polypeptide also refers to, and does not exclude, modifications of the polypeptide, e.g., glycosylation, acetylation, phosphorylation and the like. Such modifications are well described in basic texts and in more detailed monographs, as well as in the research literature.
  • the polypeptide (or protein) that is preferably meant herein is a wild-type or mutant CYCLOPS polypeptide.
  • CYCLOPS CYCLOPS
  • position when used in accordance with the present invention means the position of either an amino acid within an amino acid sequence depicted herein or the position of a nucleotide within a nucleic acid sequence depicted herein.
  • corresponding as used herein also includes that a position is not only determined by the number of the preceding nucleotides/amino acids.
  • the position of a given nucleotide in accordance with the present invention which may be substituted may vary due to deletions or additional nucleotides elsewhere in a (mutant or wild-type) CYCLOPS 5'-untranslated region (UTR) including the promoter and/or any other regulatory sequences or gene (including exons and introns).
  • UTR 5'-untranslated region
  • the position of a given amino acid in accordance with the present invention which may be substituted may very due to deletion or addition of amino acids elsewhere in a (mutant or wild-type) CYCLOPS polypeptide.
  • nucleotides/amino acids may differ in the indicated number but may still have similar neighboring nucleotides/amino acids. Said nucleotides/amino acids which may be exchanged, deleted or added are also comprised by the term "corresponding position”.
  • the skilled person may, when aligning the reference sequence (subject sequence) SEQ ID No: 1 or 2 with a nucleotide or amino acid sequence of interest (query sequence), for example, inspect a sequence of interest for the sequence motif RXXS (or the corresponding nucleotide sequence encoding this motif, respectively) when looking for the amino acid position (or codon encoding the amino acid at said position) as specified herein (i.e., a position corresponding to position 50 and/or 154 of the amino acid sequence shown in SEQ ID No:2 or a position corresponding to position 148-150 and/or 460-462 of the nucleotide sequence shown in SEQ ID No: 1 , respectively).
  • the "S” of said motif is subject to phosphorylation by a DMI3 protein such as CCaMK. Said “S” is then replaced in a mutant CYCLOPS protein by an amino acid mimicking the effects of phosphorylation.
  • nucleotide residue or amino acid residue in a given (mutant or wild-type) CYCLOPS nucleotide/amino acid sequence corresponds to a certain position in the nucleotide sequence of SEQ ID No: 1 or the amino acid sequence of SEQ ID No: 2, the skilled person can use means and methods well-known in the art, e.g., alignments, either manually or by using computer programs such as BLAST2.0, which stands for Basic Local Alignment Search Tool or ClustalW or any other suitable program which is suitable to generate sequence alignments.
  • BLAST2.0 stands for Basic Local Alignment Search Tool or ClustalW or any other suitable program which is suitable to generate sequence alignments.
  • SEQ ID No: 1 is the nucleotide sequence encoding Lotus japonicus wild type CYCLOPS.
  • SEQ ID No: 2 is the Lotus japonicus wild-type amino acid sequence derived from SEQ ID No: 1.
  • SEQ ID No: 3 is the nucleotide sequence encoding the Lotus japonicus double D mutant CYCLOPS and SEQ ID No:4 is the CYCLOPS double D mutant protein.
  • Ser Ser Ser Ser lie Gly Phe Ser Ser Arg Leu Ser Lys Arg lie Ser 65 70 75 80
  • the CYCLOPS gene comprised by a plant of the present invention may thus be regarded as a mutant/mutated CYCLOPS gene, mutant/mutated CYCLOPS allele, or variant CYCLOPS gene.
  • mutant/mutated allele refers to mutant/mutated CYCLOPS allele
  • mutant/mutated CYCLOPS gene refers to mutant/mutated CYCLOPS gene
  • nucleotide sequence which comprises at a first position corresponding to position 148- 150 of the nucleotide sequence shown in SEQ ID No: 1 and/or at a second position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid mimicking the effects of phosphorylation, or (ii) a nucleotide sequence that encodes a (mutant) CYCLOPS protein having at a first position corresponding to position 50 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 and/or at a second position corresponding to position 154 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation.
  • mutant/mutated CYCLOPS protein/polypeptide or “variant CYCLOPS protein/polypeptide” are used interchangeably and refer to
  • a CYCLOPS protein having at a first position corresponding to position 50 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 and/or at a second position corresponding to position 154 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation, or
  • a CYCLOPS protein encoded by a nucleotide sequence which comprises at a first position corresponding to position 148-150 of the nucleotide sequence shown in SEQ ID No: 1 and/or at a second position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid mimicking the effects of phosphorylation.
  • wild-type allele refers to
  • nucleotide sequence which does not comprise at a first position corresponding to position 148-150 of the nucleotide sequence shown in SEQ ID No:1 and/or at a second position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No:1 a codon encoding an amino acid mimicking the effects of phosphorylation, or
  • nucleotide sequence that encodes a CYCLOPS protein that does not have an amino acid mimicking the effects of phosphorylation, said amino acid being preferably serine, at a first position corresponding to position 50 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 and/or at a second position corresponding to position 154 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation.
  • a "wild-type CYCLOPS gene” has at a first position corresponding to position 148-150 of the nucleotide sequence shown in SEQ ID No:1 and/or at a second position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid which is capable of being phosphorylated, such as serine, threonine or tryptophane, with tryptophane being less preferred.
  • wild-type allele may, or may not, comprise mutations, other than the mutation that causes the S50D and/or S154D substitution.
  • wild-type CYCLOPS protein/polypeptide are used interchangeably and refer to
  • a CYCLOPS protein which does not have at a first position corresponding to position 50 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 and/or at a second position corresponding to position 154 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation, or
  • a CYCLOPS protein encoded by a nucleotide sequence which does not comprise at a first position corresponding to position 148-150 of the nucleotide sequence shown in SEQ ID No: 1 and/or at a second position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid mimicking the effects of phosphorylation.
  • a wild-type CYCLOPS protein has at a first position corresponding to position 50 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 and/or at a second position corresponding to position 154 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid which is capable of being phosphorylated, such as serine, threonine or tyrosine, with tyrosine being less preferred.
  • a plant of the present invention comprises a codon encoding an amino acid which mimicks the effects of phosphorylation.
  • the plant of the present invention comprises a codon encoding an amino acid which mimicks the effects of phosphorylation.
  • amino acid mimicking the effect(s) of phosphorylation means an amino acid which has/exerts the same effect and/or has the same physico-chemical properties as a phosphorylated amino acid, preferably physiological effect, as an amino acid which is phosphorylated.
  • phosphorylation of the amino acid that is then mimicked by another amino acid is preferably effected by a kinase
  • phosphorylation of an amino acid comprised by a CYCLOPS protein is preferably effected by CCaMK (i.e., a DMI3 ortholog), either in vitro or in vivo, with in vivo being preferred.
  • CCaMK i.e., a DMI3 ortholog
  • the amino acid(s) that is/are preferably phosphorylated by CCaMK is/are one or more serine(s) and/or threonine(s) comprised by a CYCLOPS protein, more preferably it is the serine residue in a CYCLOPS protein at a position corresponding to position 50 of the amino acid sequence shown in SEQ ID No:2 and/or the serine residue in a CYCLOPS protein at a position corresponding to position 154 of the amino acid sequence shown in SEQ ID No:2.
  • the amino acid mimicking the effect(s) of phosphorylation is preferably homolog, variant or the like of aspartic acid or glutamic acid which can be used in chemical synthesis of proteins, more preferably it is an acidic amino acid, even more preferably it is aspartate (Asp or D) or glutamate (Glu or E).
  • the amino acid at a position corresponding to position 50 and/or 154 of the amino acid sequence of SEQ ID No:2 is different from serine in a (mutant) CYCLOPS protein of the present invention.
  • a (mutant) CYCLOPS gene of the present invention encodes a protein comprising a S50D, S50E, S154D, S154E, S50D and S154D, S50D and S154E, S50E and S154D or S50E and S154E substitution, collectively referred to herein as CYCLOPS substitution(s).
  • a particularly preferred (mutant) CYCLOPS protein encoded by a CYCLOPS gene of the present invention comprises the S50D and S154D ("double D") substitution (sometimes also referred to herein as double D CYCLOPS (protein)).
  • a plant of present invention has in its genome the nucleotide sequence of a (mutated) CYCLOPS gene shown in SEQ ID No:3.
  • the CYCLOPS gene shown in SEQ ID No:3 encodes the double D CYCLOPS protein shown in SEQ ID No:4.
  • the S50D or S50E substitution is a result of an alteration of the codon at a position corresponding to position 148-150 of the nucleotide sequence shown in SEQ ID No: 1 . More preferably, the S50D or S50E substitution is a result of an alteration of the codon at a position corresponding to position 148-150 of the nucleotide sequence shown in SEQ ID No: 1 so that said codon encodes an amino acid mimicking the effects of phosphorylation such as an acidic amino acid, more preferably aspartate or glutamate, respectively ("D” is encoded by the codon "GAC” or "GAT", ⁇ " is encoded by the codon "GAG” or "GAA” at said position).
  • the S154D or S154E substitution is a result of an alteration of the codon at a position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No: 1. More preferably, the S154D or S154E substitution is a result of an alteration of the codon at a position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No: 1 so that said codon encodes an amino acid mimicking the effects of phosphorylation such as an acidic amino acid, more preferably aspartate or glutamate, respectively ("D” is encoded by the codon "GAC” or "GAT”, “E” is encoded by the codon "GAG” or "GAA” at said position).
  • CYCLOPS refers to a nucleotide sequence encoding a nuclear-localized protein with a coiled-coil motif or a nuclear-localized protein with a coiled-coil motif encoded by said nucleotide sequence.
  • CYCLOPS when used herein can refer to a CYCLOPS protein. The skilled person will recognize because of the context in which said term is used whether it refers to a nucleotide sequence or an amino acid sequence (protein). Similarly, the skilled person will recognize because of the context in which said term is used whether it refers to a mutant or wild-type CYCLOPS nucleotide sequence or protein, respectively, or to both.
  • the CYCLOPS protein is encoded by a gene isolated by the present inventors from Lotus japonicus (Yano et al., cited herein).
  • the CYCLOPS protein from Lotus japonicus is an ortholog of the Medicago truncatula IPD3 protein.
  • the IPD3 protein was recently identified as interacting Protein of DMI 3 (the M. truncatula CCaMK ortholog).
  • CYCLOPS comprises orthologs of the Medicago truncatula IPD3 protein or the Lotus japonicus CYCLOPS protein (sometimes also referred to herein as “IPD3 proteins” or “IPD3 class proteins”).
  • IPD3 proteins are known from diverse plants spanning from Liverworths, Mosses, Hornworts, Lycophytes, Monilophytes, Gymnosperms and Angiosperms which are also encompassed by the term “CYCLOPS” when used herein (see column 4 of Table 1 Wang et al. (2010), New Phytologist 186, 514-525)as well as and corresponding mutant derivatives thereof, i.e.
  • the IPD3 proteins disclosed in Wang et al. may be modified in accordance with the teaching of the present invention so as to comprise at a first position corresponding to position 50 and/or at a second position corresponding to position 154 of the amino acid sequence of SEQ ID No:2 an amino acid mimicking the effects of phosphorylation:
  • CYCLOPS protein The classification of a protein as CYCLOPS protein is based on its overall identity with known CYCLOPS proteins (IPD3 orthologs as described herein), which are, for example, shown in column 4 of Table 1 of Wang et al.
  • IPD3 orthologs as described herein
  • the person skilled in the art is readily in a position to determine whether a protein based on its overall identity belongs to the IPD3 class of proteins by using means and methods for generating sequence alignments or structure prediction for determining motifs of proteins, in particular in the coiled-coil domain, see below, for example, available at www.expasy.ch or http://www.isrec.isb-
  • Fig. S5 Alignment of conserved functional domains in the three mycorrhizal proteins DM11 (A), DMI3 (B), and IPD3 (C).
  • the amino acids with asterisks in IPD3 represent the nuclear localization signal.
  • a dot represents an amino acid identical to the one in the top sequence.
  • any of the (mutant) CYCLOPS proteins described herein preferably comprises at a first position corresponding to position 50 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 and/or at a second position corresponding to position 154 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation.
  • the CYCLOPS protein which comprises said amino acid mimicking the effects of phosphorylation may thus also be referred to herein as "mutated”, “substituted", or "variant" CYCLOPS protein.
  • Said mutated, substituted, or variant CYCLOPS protein is encoded by a nucleotide sequence comprising at a first position corresponding to position 148-150 of the nucleotide sequence shown in SEQ ID No: 1 and/or at a second position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid mimicking the effects of phosphorylation.
  • an activity test is shown in the appended Examples herein below.
  • it is tested whether a protein of interest can interact with CCaMK/DMI3, for example, with any one of the DMI3 proteins listed in column 3 of Table 1 of Wang et al. shown above, cited herein.
  • the preferred method for testing interaction is a two-hybrid system, for example, the yeast two-hybrid system.
  • Such an interaction is exemplified in Wang et al., cited herein (see Figure 3 of Wang et al. and Materials and Methods).
  • CYCLOPS activity of a protein of interest can alternatively and/or additionally be tested by a complementation assay. For example, it can be tested whether an inactive (or inactivated) CYCLOPS mutant which is not capable of forming nodules, in particular root nodules, for example, a Lotus japonicus CYCLOPS mutant (as described in Yano et al., cited herein) can be complemented so as to then (again) form nodules, in particular root nodules.
  • a mutant CYCLOPS protein of the present invention may be expressed in a plant to test for spontaneous nodule, in particular root nodule formation in comparison to a plant which does not express said mutant CYCLOPS protein.
  • a preferred modification of the complementation test is a complementation test done in a CCaMK (DM13) mutant, i.e., one which is not capable of forming root nodules.
  • a CCaMK (DM13) mutant i.e., one which is not capable of forming root nodules.
  • Such a mutant is, for example, described in Tirichine et al., cited herein.
  • the gene encoding the protein of interest is mutated such that it contains at a first position corresponding to position 148-150 of the nucleotide sequence shown in SEQ ID No: 1 and/or at a second position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No: 1 , a codon encoding an amino acid mimicking the effects of phosphorylation, preferably an acidic amino acid such as aspartate or glutamate.
  • a mutated gene encoding a protein of interest is introduced in a CCaMK mutant and tested for spontaneous development of nodules , in particular root nodules.
  • the gene encoding the cytokinin receptor LHK1 is inactive or that it is not constitutively active, i.e., that the plant does not have a LHK1 gain-of-function mutation which is capable of spontaneous root nodule formation (organogenesis), see Tirichine et al. (2007), Science 315, 104-107.
  • a (mutant) CYCLOPS protein encoded by a nucleotide sequence of the present invention has preferably CYCLOPS activity.
  • Said CYCLOPS activity can be tested as described before, for example, in a two hybrid assay with CCaMK (DMI3) and/or in a complementation assay.
  • activity of a (mutant) CYCLOPS protein includes preferably the capability of a plant to develop/form spontaneously root nodules, in particular root nodules (root nodule formation/organogenesis) upon expression of a (mutant) CYCLOPS nucleotide sequence as described herein.
  • spontaneous root nodule formation in a plant occurs when a plant contains and/or expresses a gene encoding a (mutant) CYCLOPS protein of the present invention which has at a first position corresponding to position 50 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 and/or at a second position corresponding to position 154 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation.
  • spontaneous root nodule formation occurs in the absence of rhizobia and/or rhizobial signal molecules.
  • organogenesis means a process by which nodules, preferably root nodules, are developed, preferably spontaneously developed, from meristematic centres.
  • the root nodules developed by the plants of the present invention containing and/or expressing a mutant CYCLOPS gene maintain an active apical meristem that produces new cells for growth over the life of the nodule.
  • nodules lose meristematic activity shortly after initiation, thus growth is due to cell expansion resulting in mature nodules which are spherical in shape.
  • nodules nitrogen gas from the atmosphere is converted into ammonia, which is then assimilated into amino acids, nucleotides, chlorophyll and other cellular constituents such as vitamins, flavones, and hormones.
  • Their ability to fix gaseous nitrogen makes legumes an ideal agricultural organism as their requirement for nitrogen fertilizer is reduced. Indeed high nitrogen content blocks nodule development as there is no benefit for the plant of forming the symbiosis.
  • the energy for splitting the nitrogen gas in the nodule comes from sugar that is translocated from the leaf (a product of photosynthesis). Malate as a breakdown product of sucrose is the direct carbon source for the bacteroid.
  • Nitrogen fixation in the nodule is very oxygen sensitive.
  • Legume nodules harbor an iron containing protein called leghaemoglobin, closely related to animal myoglobin, to facilitate the conversion of nitrogen gas to ammonia.
  • spontaneous root nodule formation occurs in the absence of rhizobia and/or rhizobial signal molecules if a plant of the present invention contains and/or expresses a gene encoding a (mutant) CYCLOPS protein as described herein, this does not mean that root nodules formed by a plant of the present invention are infected and then colonized by arbuscular mycorrhiza and/or rhizobes. It merely means that nodules, in particular root nodules are spontaneously formed/develop by plants because of containing and/or expressing a (mutant) CYCLOPS protein as described herein.
  • a plant of the present invention comprises a nucleotide sequence of a (mutant) CYCLOPS gene encoding a CYCLOPS protein having at a first position corresponding to position 50 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 and/or at a second position corresponding to position 154 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation.
  • the (mutant) CYCLOPS protein has an amino acid sequence which is at least 30%, more preferably of at least 40%, even more preferably of at least 50%, particularly preferred at least 60%, even particularly preferred at least 70%, especially preferred at least 80% and even more particularly preferred at least 90% identical to the amino acid sequence of SEQ ID No:2 and which has at a first position corresponding to position 50 of the amino acid sequence shown in SEQ ID No: 2 and/or at a second position corresponding to position 154 of the amino acid sequence shown in SEQ ID No: 2 an amino acid mimicking the effects of phosphorylation.
  • the identity is preferably over the full length of the sequences being compared.
  • such a (mutant) CYCLOPS protein has CYCLOPS activity as described herein.
  • Percent (%) amino acid sequence identity with respect to (mutant and wild-type) CYCLOPS amino acid sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence(sequence of interest) that are identical with the amino acid residues in the CYCLOPS amino acid sequence shown in SEQ ID No:2 or SEQ ID No:4, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publically available computer software such as BLAST, ALIGN, or Megalign (DNASTAR) software.
  • the degree of identity is preferably over the entire length with the amino acid sequence of SEQ ID No:2 or SEQ ID No:4.
  • an amino acid sequence of interest is aligned with the amino acid sequence of SEQ ID No:2 or SEQ ID No:4 and the identical amino acids are determined.
  • the present invention relates to a nucleic acid comprising the nucleotide sequence of a (mutant) CYCLOPS gene, wherein said nucleotide sequence comprises at a first position corresponding to position 148-150 of the nucleotide sequence shown in SEQ ID No:1 and/or at a second position corresponding to position 460-463 of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid mimicking the effects of phosphorylation. Accordingly, the nucleotide sequences of the present invention encode a CYCLOPS protein.
  • the (mutant) nucleic acid is selected from the group consisting of: (a) a nucleotide sequence having at least 30% identity to the nucleotide sequence shown in SEQ ID No: 1 and having at a first position corresponding to position 148-150 of the nucleotide sequence shown in SEQ ID No:1 and/or at a second position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid mimicking the effects of phosphorylation, said nucleotide sequence encodes a CYCLOPS protein;
  • nucleotide sequence (e) a fragment of the nucleotide sequence of (a), (b), (c) or (d), wherein the nucleotide sequence comprised by said fragment has at a first position corresponding to position 148-150 of the nucleotide sequence shown in SEQ ID No: 1 and/or at a second position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid mimicking the effects of phosphorylation, said fragment encodes a CYCLOPS protein, or
  • nucleotide sequence which is complementary to a nucleotide sequence of any one of (a), (b), (c), or (d).
  • the identity is preferably over the full length of the sequences being compared.
  • nucleic acid sequence has a certain degree of identity to the nucleic acid sequence encoding a (mutant or wild-type) CYCLOPS protein of the present invention
  • skilled person can use means and methods well-known in the art, e.g., alignments, either manually or by using computer programs such as those mentioned further down below in connection with the definition of the term "hybridization” and degrees of homology.
  • BLAST2.0 which stands for Basic Local Alignment Search Tool (Altschul, Nucl. Acids Res. 25 (1997), 3389-3402; Altschul, J. Mol. Evol. 36 (1993), 290-300; Altschul, J. Mol. Biol. 215 (1990), 403-410), can be used to search for local sequence alignments.
  • BLAST produces alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in determining exact matches or in identifying similar sequences.
  • the fundamental unit of BLAST algorithm output is the High-scoring Segment Pair (HSP).
  • An HSP consists of two sequence fragments of arbitrary but equal lengths whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user.
  • the BLAST approach is to look for HSPs between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance.
  • the parameter E establishes the statistically significant threshold for reporting database sequence matches. E is interpreted as the upper bound of the expected frequency of chance occurrence of an HSP (or set of HSPs) within the context of the entire database search. Any database sequence whose match satisfies E is reported in the program output.
  • the present invention relates to nucleic acids which hybridize to a nucleotide sequence encoding a (mutant) CYCLOPS protein described herein.
  • hybridizing nucleic acids comprise a nucleotide sequence comprising a first codon encoding an amino acid mimicking the effects of phosphorylation at a position corresponding to position 148-150 of the nucleotide sequence of the CYCLOPS gene shown in SEQ ID No: 1 and/or at a second codon encoding an amino acid mimicking the effects of phosphorylation at a position corresponding to position 460-462 of the nucleotide sequence of the CYCLOPS gene shown in SEQ ID No: 1.
  • hybridizes as used in accordance with the present invention may relate to hybridizations under stringent or non-stringent conditions. If not further specified, the conditions are preferably non-stringent. Said hybridization conditions may be established according to conventional protocols described, for example, in Sambrook, Russell “Molecular Cloning, A Laboratory Manual”, Cold Spring Harbor Laboratory, N.Y. (2001); Ausubel, “Current Protocols in Molecular Biology”, Green Publishing Associates and Wiley Interscience, N.Y. (1989), or Higgins and Hames (Eds.) "Nucleic acid hybridization, a practical approach” IRL Press Oxford, Washington DC, (1985). The setting of conditions is well within the skill of the artisan and can be determined according to protocols described in the art.
  • Non- stringent hybridization conditions for the detection of homologous or not exactly complementary sequences may be set at 6xSSC, 1 % SDS at 65°C.
  • the length of the probe and the composition of the nucleic acid to be determined constitute further parameters of the hybridization conditions. Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations.
  • Hybridizing nucleic acid molecules also comprise fragments of the above described molecules. Such fragments may represent nucleic acid sequences which encode a CYCLOPS protein, and which have a length of at least 12 nucleotides, preferably at least 15, more preferably at least 18, more preferably of at least 21 nucleotides, more preferably at least 30 nucleotides, even more preferably at least 40 nucleotides and most preferably at least 60 nucleotides and comprise a nucleotide sequence comprising a first codon encoding an amino acid mimicking the effects of phosphorylation at a position corresponding to position 148-150 of the nucleotide sequence of the CYCLOPS gene shown in SEQ ID No: 1 and/or at a second codon encoding an amino acid mimicking the effects of phosphorylation at a position corresponding to position 460-462 of the nucleotide
  • nucleic acid molecules which hybridize with any of the aforementioned nucleic acid molecules also include complementary fragments, derivatives and allelic variants of these molecules.
  • a hybridization complex refers to a complex between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration.
  • a hybridization complex may be formed in solution (e.g., Cot or Rot analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., membranes, filters, chips, pins or glass slides to which, e.g., cells have been fixed).
  • a solid support e.g., membranes, filters, chips, pins or glass slides to which, e.g., cells have been fixed.
  • complementary or complementarity refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base-pairing.
  • the sequence "A-G-T” binds to the complementary sequence "T-C-A”.
  • Complementarity between two single-stranded molecules may be "partial", in which only some of the nucleic acids bind, or it may be complete when total complementarity exists between single-stranded molecules.
  • the degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybrid
  • hybridizing sequences preferably refers to sequences which display a sequence identity of at least 30 or 40%, preferably at least 50%, more preferably at least 60%, even more preferably at least 70%, particularly preferred at least 80%, more particularly preferred at least 90%, even more particularly preferred at least 95%, 96%, 97% or 98% and most preferably at least 99% identity with a nucleic acid sequence as described above encoding a (mutant) CYCLOPS protein.
  • hybridizing sequences comprise a nucleotide sequence comprising a first codon encoding an amino acid mimicking the effects of phosphorylation at a position corresponding to position 148-150 of the nucleotide sequence of the CYCLOPS gene shown in SEQ ID No: 1 and/or at a second codon encoding an amino acid mimicking the effects of phosphorylation at a position corresponding to position 460-462 of the nucleotide sequence of the CYCLOPS gene shown in SEQ ID No: 1.
  • hybridizing sequences preferably refers to sequences encoding a CYCLOPS protein having a sequence identity of at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, particularly preferred at least 70%, more particularly preferred at least 80%, even more particularly preferred at least 90%, 95% or 98% and most preferably at least 99% identity with an amino acid sequence of a CYCLOPS protein shown in SEQ ID No:2.
  • hybridizing sequences encode a CYCLOPS protein having at a first position corresponding to position 50 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 and/or at a second position corresponding to position 154 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation.
  • Percent (%) nucleotide sequence identity with respect to (mutant or wild-type) CYCLOPS nucleotide sequences identified herein is defined as the percentage of nucleotide residues in a candidate sequence (sequence of interest) that are identical with the nucleotide residues in the CYCLOPS nucleotide sequence shown in SEQ ID No: 1 or 3 after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity.
  • Alignment for purposes of determining percent nucleotide sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publically available computer software such as BLAST, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximum alignment over the full length of the sequences being compared.
  • the degree of identity is preferably over the entire length with the nucleotide sequence of SEQ ID No: 1 or 3.
  • a nucleotide sequence of interest is aligned with the nucleotide sequence of SEQ ID No: 1 or 3 and the identical nucleotide residues are determined.
  • Such a definition also applies to the complement of a test sequence.
  • the described identity exists over a region that is at least about 15 to 25 nucleotides in length, more preferably, over a region that is about 50 to 100 nucleotides in length.
  • Nucleic acids which hybridize with the nucleic acids disclosed herein can for instance be isolated from genomic libraries or cDNA libraries of bacteria, fungi, plants or animals. Preferably, such nucleic acids are from plant origin. Preferably, nucleic acids which hybridize to the nucleotide sequence of SEQ ID No: 1 or 3 are variants, analogs or paralogs of such a nucleotide sequence.
  • analogs refers to two nucleic acids that have the same or similar function, but that have evolved separately in unrelated organisms.
  • orthologs refers to two nucleic acids from different species, but that have evolved from a common ancestral gene by speciation. Normally, orthologs encode polypeptides having the same or similar functions.
  • paralogs refers to two nucleic acids that are related by duplication within a genome. Paralogs usually have different functions, but these functions may be related (Tatusov, R. L. et al., 1997, Science 278, 631- 637).
  • fragments are understood to mean parts of the nucleotide sequences of the present invention which are long enough to encode a protein having (mutant) CYCLOPS activity, preferably showing the biological activity as described above and which comprise a first codon encoding an amino acid mimicking the effects of phosphorylation at a position corresponding to position 148-150 of the nucleotide sequence of the CYCLOPS gene shown in SEQ ID No: 1 and/or at a second codon encoding an amino acid mimicking the effects of phosphorylation at a position corresponding to position 460-462 of the nucleotide sequence of the CYCLOPS gene shown in SEQ ID No: 1.
  • a fragment of a (mutant) CYCLOPS nucleotide sequence has preferably a length of at least 15, 30, 45, 60, 100, 150, 200, 250, 300, 350, 400, 450 or 500 nucleotides.
  • nucleic acids comprising a nucleotide sequence described herein are preferably comprised and/or expressed by a plant of the present invention. Such nucleic acids are comprised by the term "CYCLOPS”.
  • the present invention relates to a plant encoding a CYCLOPS protein having at a first position corresponding to position 50 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 and/or at a second position corresponding to position 154 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation.
  • a plant preferably contains and/or expresses a nucleic acid comprising a nucleotide sequence encoding a (mutated) CYCLOPS gene as described herein.
  • polypeptide or fragment thereof encoded by a nucleic acid described herein is a further aspect of the present invention.
  • proteins are described in detail elsewhere herein and are encompassed by the term "CYCLOPS”.
  • a fragment of a (mutant) CYCLOPS protein has a length of at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250 or 300 amino acids.
  • Said fragment prefeably comprises an amino acid having at a first position corresponding to position 50 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 and/or at a second position corresponding to position 154 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation.
  • nucleic acids comprising a (mutant) nucleotide sequence described herein which are preferably comprised by a plant are preferably integrated (preferably stably integrated) in the genome of said plant. However, it is also envisaged that said nucleic acids are present extrachromosomally in said plant. Extrachromosomal presence may be desirable in case of transient expression.
  • a (mutant) CYCLOPS nucleic acid as described herein is integrated into a plant of the present invention, the plant as a result of said integration may be transgenic or non-transgenic.
  • non-transgenic plant preferably a plant lacking a heterologous nucleotide sequence in its genome in at least one, preferably in each endogenous CYCLOPS locus. Said non-transgenic plant, however, contains preferably the mutant CYCLOPS gene as described herein. [0101] Accordingly, it is a preferred embodiment of the present invention that the plant is a non-transgenic plant.
  • Such a non-transgenic plant comprises in the nucleotide sequence of at least one CYCLOPS gene in its endogenous gene locus, one codon encoding an amino acid mimicking the effects of phosphorylation at a position as specified herein or two codons encoding an amino acid mimicking the effects of phosphorylation at the positions as specified herein .
  • CYCLOPS gene in its endogenous locus it is meant that the CYCLOPS gene comprised by a plant of the present invention is - when compared to a wild-type plant - located in the same locus, i.e., the CYCLOPS gene is positioned (located) on the same chromosome in the same chromosomal context (organization) as it is positioned in a wild- type plant (i.e., without there being any human intervention so as to transfer or re-locate the CYCLOPS gene comprised by the plant of the present invention to another location such as to a chromosome or genomic locus (position) different from that where the CYCLOPS gene is naturally located). Accordingly, the same genome-specific satellite markers which surround a wild-type CYCLOPS gene also surround the CYCLOPS gene comprised by a plant of the present invention.
  • Chrosomal context means that a (mutant) CYCLOPS gene of a plant of the present invention is located on the same chromosome as it is in a corresponding wild-type plant at the same location as it is in a wild-type plant. Accordingly, the same genes as in a wild-type plant are adjacent to the 5'- and 3'-end of the CYCLOPS gene comprised by a plant of the present invention. Accordingly, the same nucleotide sequences which are adjacent to the 5'- and 3'-end of the wild-type CYCLOPS gene are adjacent to the 5'- and 3'-end of the CYCLOPS gene comprised by a plant of the present invention.
  • the similarity of the chromosomal context between the (mutant) CYCLOPS gene comprised by a plant of the present invention and that of the CYCLOPS gene of a corresponding wild-type plant can, for example, be tested as follows:
  • genome-specific satellite markers which surround a wild-type CYCLOPS gene and the (mutated) CYCLOPS gene of the present invention can be used together with sequences from the CYCLOPS gene (except for the codon(s) at the position as specified herein which is/are different between the wild-type CYCLOPS gene and the mutant CYCLOPS gene comprised by a plant of the present invention) for primer design and subsequent nucleic acid amplification, whereby the amplification product will be identical between a wild-type plant and a plant of the present invention.
  • genome-specific satellite markers can also be used for a fluorescent in situ hybridization (FISH) in order to check the location of the CYCLOPS gene
  • FISH fluorescent in situ hybridization
  • the "staining pattern" in FISH of the chromosome on which the wild-type CYCLOPS gene is located will be identical to the staining pattern in FISH of the chromosome on which the (mutated) CYCLOPS gene of the present invention is located.
  • the plant is a transgenic plant.
  • the present invention relates also to transgenic plant cells which contain a nucleic acid molecule as described herein encoding a (mutated) CYCLOPS protein, wherein the nucleic acid molecule is foreign to the transgenic plant cell.
  • nucleic acid molecule is either heterologous with respect to the plant cell, this means derived from a cell or organism with a different genomic background, or is homologous with respect to the plant cell but located in a different genomic environment than the naturally occurring counterpart of said nucleic acid molecule.
  • the nucleic acid molecule may be either under the control of its own promoter or under the control of a heterologous promoter.
  • Plants of the present invention can, for example, be produced by site directed mutagenesis methods including those methods disclosed, for example, in International Application PCT/USOO/23457, or U.S. Patent Nos. 6,271 ,360, 6,479,292, and 7,094,606.
  • site directed mutagenesis methods may involve the use of oligonucleotide-directed gene repair to introduce point mutations into the host cell genome, and can involve the use of single- stranded oligonucleotides, such as gene repair oligonucleobases (See, U.S. Patent Nos. 6,870,075 and 5,565,350).
  • RTDS Rapid Trait Development SystemTM
  • RTDS is based on altering a targeted gene by utilizing the cell's own gene repair system to specifically modify the gene sequence in situ and not insert foreign DNA and gene expression control sequences. This procedure effects a precise change in the genetic sequence while the rest of the genome is left unaltered.
  • GMOs Rapid Trait Development System
  • the RTDS that effects this change is a chemically synthesized oligonucleotide which may be composed of both DNA and modified RNA bases as well as other chemical moieties, and is designed to hybridize at the targeted gene location to create a mismatched base-pair(s).
  • This mismatched base-pair acts as a signal to attract the cell's own natural gene repair system to that site and correct (replace, insert or delete) the designated nucleotide(s) within the gene.
  • the RTDS molecule is degraded and the now-modified or repaired gene is expressed under that gene's normal endogenous control mechanisms.
  • RTDS is a site-specific gene modification system that is effective at making precise changes in a gene sequence without the incorporation of foreign genes or control sequences.
  • RTDS is described in detail in Beetham et al. (1999), Proc. Natl. Acad. Sci. USA Vol. 96: 8774-8778; Zhu et al. (1999), Proc. Natl. Acad. Sci. USA Vol. 96, pp. 8768-8773, Zhu et al. (2000), Nat. Biotechnol. Vol. 18:555-558, Kochevenko and Willmitzer (2003), Plant Physiology, Vol. 132: 174-184; Okuzaki and Toriyama (2004), Plant Cell Rep 22:509-512 or Dong et al. (2006), Plant Cell Rep 25: 457-465.
  • SSMOVs single-stranded oligonucleotide mutational vectors
  • SSMOVs can be prepared in accordance with International Patent Application PCT/USOO/23457 and U.S. Patent Nos. 6,271 ,360; 6,479,292; and 7,094,606.
  • the sequence of the SSOMV can be based on the same principles as the mutational vectors described in U.S. Pat. Nos.
  • the sequence of the SSOMV contains two regions that are homologous with the target sequence separated by a region that contains the desired genetic alteration, termed the mutator region.
  • the mutator region can have a sequence that is the same length as the sequence that separates the homologous regions in the target sequence, but having a different sequence. Such a mutator region can cause a substitution.
  • the homologous regions in the SSOMV can be contiguous to each other, while the regions in the target gene having the same sequence are separated by one, two or more nucleotides.
  • a SSOMV causes a deletion from the target gene of the nucleotides that are absent from the SSOMV.
  • the sequence of the target gene that is identical to the homologous regions may be adjacent in the target gene but separated by one two or more nucleotides in the sequence of the SSOMV. Such an SSOMV causes an insertion in the sequence of target gene.
  • the nucleotides of the SSOMV are deoxyribonucleotides that are linked by unmodified phosphodiester bonds except that the 5' terminal and/or 3' terminal internucleotide linkage or alternatively the two 5' terminal and/or 3' terminal internucleotide linkages can be a phosphorothioate or phosphoamidate.
  • an internucleotide linkage is the linkage between nucleotides of the SSOMV and does not include the linkage between the 5' end nucleotide or 3' end nucleotide and a blocking substituent.
  • the length of the SSOMV is between 21 and 60 deoxynucleotides and the lengths of the homology regions are, accordingly, a total length of at least 20 deoxynucleotides and at least two homology regions should each have lengths of at least 8 deoxynucleotides.
  • the SSOMVs can be designed to be complementary to either the coding or the non- coding strand of the target gene.
  • the desired mutation is a substitution of a single base
  • both the mutator nucleotide be a pyrimidine.
  • both the mutator nucleotide and the targeted nucleotide in the complementary strand be pyrimidines.
  • the SSOMVs that encode transversion mutations, i.e., a C or T mutator nucleotide is mismatched, respectively, with a C or T nucleotide in the complementary strand.
  • the SSOMV can contain a 5' blocking substituent that is attached to the 5' terminal carbons through a linker.
  • the chemistry of the linker can be any chemistry and is at least 6 atoms long, and the linker is preferably flexible.
  • a variety of non-toxic substituents such as biotin, cholesterol or other steroids or a non-intercalating cationic fluorescent dye can be used.
  • examples of reagents to make SSOMV include the reagents sold as Cy3TM and Cy5TM by Glen Research, Sterling Va. (now GE Healthcare), which are blocked phosphoroamidites that upon incorporation into an oligonucleotide yield 3,3,3',3'-tetramethyl ⁇ , ⁇ '-isopropyl substituted indomonocarbocyanine and indodicarbocyanine dyes, respectively.
  • the reagent is Cy3.
  • the indocarbocyanine When the indocarbocyanine is N-oxyalkyl substituted it can be conveniently linked to the 5' terminal of the oligodeoxynucleotide through a phosphodiester bond with a 5' terminal phosphate.
  • the chemistry of the dye linker between the dye and the oligodeoxynucleotide is not critical and is chosen for synthetic convenience.
  • the commercially available Cy3 phosphoramidite is used as directed the resulting 5' modification consists of a blocking substituent and linker together which are a N- hydroxypropyl, N'-phosphatidylpropyl 3, 3,3', 3'- tetramethyl indomonocarbocyanine.
  • the indocarbocyanine dye is tetra substituted at the 3 and 3' positions of the indole rings. Without limitations as to theory these substitutions prevent the dye from being an intercalating dye.
  • the identity of the substituents at these positions is not critical.
  • the SSOMV can, in addition, have a 3' blocking substituent. Again the chemistry of the 3' blocking substituent is not critical.
  • introduction or “transformation” as referred to herein encompasses the transfer of an exogenous nucleic acid into a host cell, irrespective of the method used for transfer.
  • Plant tissue capable of subsequent clonal propagation may be transformed with a genetic construct of the present invention and a whole plant regenerated there from.
  • the particular tissue chosen will vary depending on the clonal propagation systems available for, and best suited to, the particular species being transformed.
  • Exemplary tissue targets include leaf disks, pollen, embryos, cotyledons, hypocotyls, megagametophytes, callus tissue, existing meristematic tissue (e.g., apical meristem, axillary buds, and root meristems), and induced meristem tissue (e.g., cotyledon meristem and hypocotyl meristem).
  • the polynucleotide may be transiently or stably introduced into a host cell and may be maintained non-integrated, for example, as a plasmid. Alternatively, it may be integrated into the host genome.
  • the resulting transformed plant cell may then be used to regenerate a transformed plant in a manner known to persons skilled in the art.
  • Transformation of plant species is now a fairly routine technique.
  • any of several transformation methods may be used to introduce the gene of interest into a suitable ancestor cell.
  • the methods described for the transformation and regeneration of plants from plant tissues or plant cells may be utilized for transient or for stable transformation. Transformation methods include the use of liposomes, electroporation, chemicals that increase free DNA uptake, injection of the DNA directly into the plant, particle gun bombardment, transformation using viruses or pollen and microprojection. Methods may be selected from the calcium/polyethylene glycol method for protoplasts (Krens, F.A. et al., (1982) Nature 296, 72- 74; Negrutiu I et al.
  • Transgenic plants including transgenic crop plants, are preferably produced via Agrobacterium-mediated transformation.
  • An advantageous transformation method is the transformation in planta.
  • agrobacteria it is possible, for example, to allow the agrobacteria to act on plant seeds or to inoculate the plant meristem with agrobacteria. It has proved particularly expedient in accordance with the invention to allow a suspension of transformed agrobacteria to act on the intact plant or at least on the flower primordia. The plant is subsequently grown on until the seeds of the treated plant are obtained (Clough and Bent, Plant J. (1998) 16, 735- 743).
  • Methods for Agrobacterium-mediated transformation of rice include well known methods for rice transformation, such as those described in any of the following: European patent application EP 1198985 A1 , Aldemita and Hodges (Planta 199: 612-617, 1996); Chan et al. (Plant Mol Biol 22 (3): 491-506, 1993), Hiei et al. (Plant J 6 (2): 271-282, 1994), which disclosures are incorporated by reference herein as if fully set forth.
  • the preferred method is as described in either Ishida et al. (Nat. Biotechnol 14(6): 745-50, 1996) or Frame et al.
  • the nucleic acids or the construct to be expressed is preferably cloned into a vector, which is suitable for transforming Agrobacterium tumefaciens, for example pBin19 (Bevan et al., Nucl. Acids Res. 12 (1984) 871 1 ).
  • Agrobacteria transformed by such a vector can then be used in known manner for the transformation of plants, such as plants used as a model, like Arabidopsis ⁇ Arabidopsis thaliana is within the scope of the present invention not considered as a crop plant), or crop plants such as, by way of example, tobacco plants, for example by immersing bruised leaves or chopped leaves in an agrobacterial solution and then culturing them in suitable media.
  • the transformation of the chloroplast genome is generally achieved by a process which has been schematically displayed in Klaus et al., 2004 (Nature Biotechnology 22 (2), 225-229). Briefly the sequences to be transformed are cloned together with a selectable marker gene between flanking sequences homologous to the chloroplast genome. These homologous flanking sequences direct site specific integration into the plastome. Plastidal transformation has been described for many different plant species and an overview is given in Bock (2001 ) Transgenic plastids in basic research and plant biotechnology. J Mol Biol. 2001 Sep 21 ; 312 (3):425-38 or Maliga, P (2003) Progress towards commercialization of plastid transformation technology. Trends Biotechnol. 21 , 20-28. Further biotechnological progress has recently been reported in form of marker free plastid transformants, which can be produced by a transient co- integrated maker gene (Klaus et al., 2004, Nature Biotechnology 22(2), 225-229).
  • T-DNA activation tagging involves insertion of T- DNA, usually containing a promoter (may also be a translation enhancer or an intron), in the genomic region of the gene of interest or 10 kb up- or downstream of the coding region of a gene in a configuration such that the promoter directs expression of the targeted gene.
  • a promoter may also be a translation enhancer or an intron
  • T-DNA is randomly inserted into the plant genome, for example, through Agrobacterium infection and leads to modified expression of genes near the inserted T-DNA.
  • the resulting transgenic plants show dominant phenotypes due to modified expression of genes close to the introduced promoter.
  • TILLING is an abbreviation of "Targeted Induced Local Lesions In Genomes” and refers to a mutagenesis technology useful to generate and/or identify nucleic acids encoding proteins with modified expression and/or activity. TILLING also allows selection of plants carrying such mutant variants. These mutant variants may exhibit modified expression, either in strength or in location or in timing (if the mutations affect the promoter for example). These mutant variants may exhibit higher activity than that exhibited by the gene in its natural form. TILLING combines high-density mutagenesis with high-throughput screening methods.
  • Any of the plants of the present invention which contains and/or expresses a mutated CYCLOPS gene as described herein is preferably agronomically exploitable.
  • Agronomically exploitable means that the plants of the present invention are useful for agronomical purposes.
  • the plants, though containing and/or expressing a (mutated) CYCLOPS gene should grow normally, preferably like a corresponding wild-type plant, serve for the purpose of being useful for crop production, fruit production, etc.
  • a skilled person knows that, if a plant which contains and/or expresses a (mutated) CYCLOPS gene may not grow normally, appropriate measures such as backcrossing have to be taken.
  • the present invention relates to harvestable parts or propagation material of the plant of the present invention.
  • propagation material comprises those components or parts of the plant which are suitable to produce offspring vegetatively or generatively. Suitable means for vegetative propagation are for instance cuttings, callus cultures, rhizomes or tubers. Other propagation material includes for instance fruits, seeds, seedlings, protoplasts, cell cultures etc. The preferred propagation materials are tubers and seeds.
  • the invention also relates to harvestable parts of the plants of the invention such as, for instance, fruits, seeds, tubers, rootstocks, leaves, flowers, oil, meal or protein.
  • any harvestable parts or material of a plant described herein contains up to 2%, 1 %, 0.5%, 0.25%, 0.1 %, 0.05%, 0.025%, 0.01 %, 0.005% or 0.001 % (w/w) or (w/v) or (v/v), dependent on the form of said harvestable parts or material, of a (mutant) nucleotide sequence or fragment as described herein or a (mutant) amino acid sequence or fragment as described herein.
  • Said mutant nucleotide sequence comprises comprises at least one (preferably two) of the codons at the position(s) as specified herein which encode an amino acid mimicking the effects of phosphorylation.
  • said mutant amino acid sequence comprises at least one (preferably) two of the amino acids at the positions as specified herein that mimick the effects of phosphorylation.
  • the present invention relates to vectors, in particular plasmids, cosmids, viruses, bacteriophages and other vectors commonly used in genetic engineering, which contain the nucleic acids, prerefably the mutant nucleic acids of the present invention.
  • the vectors of the invention are suitable for the transformation of fungal cells, cells of microorganisms such as yeast or bacterial cells, animal cells or, in particular, plant cells.
  • Plant cell includes, without limitation, algae, cyanobacteria, seeds, suspension cultures, embryos, meristematic regions, callus tissue, leaves, roots, shoots, gametophytes, sporophytes, pollen, and microspores.
  • such vectors are suitable for the transformation of plants.
  • a (mutant) nucleic acid of the present invention which may preferably be comprised by a vector is operatively linked with an expression control sequence and/or with a termination signal sequence. Accordingly, a (mutant) nucleic acid of the present invention may preferably contain heterologous nucleotide sequences such as an expression control sequence and/or a termination signal sequence.
  • progeny of the plant can also comprise the heterologous nucleotide sequences.
  • a progeny plant that comprises at least a portion of the heterologous nucleotide sequences of at least one progenitor transgenic plant is also a transgenic plant.
  • heterologous means that the nucleotide sequence either originates from a species different from that into which it is transformed or it may nevertheless originate from the same species, but be inserted at a location different from that where it originates from.
  • operatively linked refers to a functional linkage between one or more expression control sequences and the coding region of the heterologous nucleotide sequence such that the promoter sequence is able to initiate transcription of the gene of interest.
  • expression means the transcription of a specific gene or specific genes or specific genetic construct.
  • expression in particular means the transcription of a gene or genes or genetic construct into structural RNA (rRNA, tRNA) or mRNA with or without subsequent translation of the latter into a protein. The process includes transcription of DNA and processing of the resulting mRNA product.
  • Regulatory elements ensuring expression in plant cells are well known to those skilled in the art. They encompass promoters, enhancers, termination signals, targeting signals and the like. Examples are given further below in connection with explanations concerning vectors.
  • expression control sequences may comprise poly-A signals ensuring termination of transcription and stabilization of the transcript, for example, those of the 35S RNA from Cauliflower Mosaic Virus (CaMV) or the nopaline synthase gene from Agrobacterium tumefaciens. Additional regulatory elements may include transcriptional as well as translational enhancers. A plant translational enhancer often used is the CaMV omega sequences. Similarly, the inclusion of an intron (e.g. intron-1 from the shrunken gene of maize) has been shown to increase expression levels by up to 100-fold (Mait, Transgenic Research 6 (1997), 143-156; Ni, Plant Journal 7 (1995), 661-676).
  • intron e.g. intron-1 from the shrunken gene of maize
  • regulatory element control sequence
  • promoter typically refers to a nucleic acid control sequence located upstream from the transcriptional start of a gene and which is involved in recognising and binding of RNA polymerase and other proteins, thereby directing transcription of an operably linked nucleic acid.
  • transcriptional regulatory sequences derived from a classical eukaryotic genomic gene (including the TATA box which is required for accurate transcription initiation, with or without a CCAAT box sequence) and additional regulatory elements (i.e. upstream activating sequences, enhancers and silencers) which alter gene expression in response to developmental and/or external stimuli, or in a tissue-specific manner.
  • additional regulatory elements i.e. upstream activating sequences, enhancers and silencers
  • a transcriptional regulatory sequence of a classical prokaryotic gene in which case it may include a -35 box sequence and/or -10 box transcriptional regulatory sequences.
  • a "plant promoter” comprises regulatory elements, which mediate the expression of a coding sequence segment in plant cells. Accordingly, a plant promoter need not be of plant origin, but may originate from viruses or micro-organisms, for example from viruses which attack plant cells.
  • the "plant promoter” can also originate from a plant cell, e.g. from the plant which is transformed with the nucleic acid sequence to be expressed in the inventive process and described herein. This also applies to other "plant” regulatory signals, such as "plant” terminators.
  • the promoters upstream of the nucleotide sequences useful in the methods of the present invention can be modified by one or more nucleotide substitution(s), insertion(s) and/or deletion(s) without interfering with the functionality or activity of either the promoters, the open reading frame (ORF) or the 3'-regulatory region such as terminators or other 3' regulatory regions which are located away from the ORF. It is furthermore possible that the activity of the promoters is increased by modification of their sequence, or that they are replaced completely by more active promoters, even promoters from heterologous organisms.
  • the nucleic acid molecule must, as described above, be linked operably to or comprise a suitable promoter which expresses the gene at the right point in time and with the required spatial expression pattern.
  • the promoter used may be a constitutive promoter or an organ-specific/tissue- specific promoter.
  • a "constitutive promoter” refers to a promoter that is transcriptionally active during most, but not necessarily all, phases of growth and development and under most environmental conditions, in at least one cell, tissue or organ.
  • An organ-specific or tissue-specific promoter is one that is capable of preferentially initiating transcription in certain organs or tissues, such as the leaves, roots, seed tissue etc.
  • a "root-specific promoter” is a promoter that is transcriptionally active predominantly in plant roots, substantially to the exclusion of any other parts of a plant, whilst still allowing for any leaky expression in these other plant parts. Promoters able to initiate transcription in certain cells only are referred to herein as "cell-specific”.
  • a seed-specific promoter is transcriptionally active predominantly in seed tissue, but not necessarily exclusively in seed tissue (in cases of leaky expression).
  • the seed-specific promoter may be active during seed development and/or during germination.
  • the seed specific promoter may be endosperm/aleurone/embryo specific. Examples of seed-specific promoters are known in the art. Further examples of seed-specific promoters are given in Qing Qu and Takaiwa (Plant Biotechnol. J. 2, 1 13-125, 2004).
  • a green tissue-specific promoter as defined herein is a promoter that is transcriptionally active predominantly in green tissue, substantially to the exclusion of any other parts of a plant, whilst still allowing for any leaky expression in these other plant parts.
  • Another example of a tissue-specific promoter is a meristem-specific promoter, which is transcriptionally active predominantly in meristematic tissue, substantially to the exclusion of any other parts of a plant, whilst still allowing for any leaky expression in these other plant parts.
  • terminal encompasses a control sequence which is a DNA sequence at the end of a transcriptional unit which signals 3' processing and polyadenylation of a primary transcript and termination of transcription.
  • the terminator can be derived from the natural gene, from a variety of other plant genes, or from T-DNA.
  • the terminator to be added may be derived from, for example, the nopaline synthase or octopine synthase genes, or alternatively from another plant gene.
  • a heterologous nucleotide sequence may also comprise a selectable marker. A selectable marker may be used for selecting plants transformed with a (mutant) nucleotide sequence as described herein.
  • Another embodiment of the invention relates to host cells, in particular prokaryotic or eukaryotic cells, genetically engineered with the (mutant) nucleic acids or vectors of the present invention or which are obtainable by a method for producing genetically engineered host cells, as well as to cells derived from such transformed host cells.
  • the host cell of the present invention is a bacterial, yeast, fungus, plant or animal cell, with a plant cell being particularly preferred.
  • the present invention relates to a method for the production of a plant being capable developing nodules, preferably spontaneously developing root nodules, preferably in the absence of rhizobia and/or rhizobial signal molecules upon expressing the (mutant) nucleotide sequence of a nucleic acid molecule as described herein encoding a mutant CYCLOPS protein comprising the introduction of a nucleic acid or a vector as described herein into the genome of a plant, plant cell or plant tissue.
  • a plant cell is obtainable (obtained). Accordingly, a plant cell obtainable (obtained) according to the afore described method is yet another aspect of the present invention
  • the present invention provides a method for the production of a plant being capable of spontaneously developing nodules, in particular root nodules, preferably in the absence of rhizobia and/or rhizobial signal molecules, in the absence of CCaMK activity (for example, because of a constitutively active CCaMK (DMI3 ortholog) and/or LHK1 activity (for example, because of a constitutively active LHK1 cytokinin receptor) comprising transforming a plant with a foreign nucleic acid molecule the presence or expression of which in the cells of said plant results in the spontaneous development of root nodules, preferably in the absence of rhizobia and/or rhizobial signal molecules.
  • CCaMK activity for example, because of a constitutively active CCaMK (DMI3 ortholog) and/or LHK1 activity (for example, because of a constitutively active LHK1 cytokinin receptor)
  • the plant transformed with said foreign nucleic acid molecule does preferably not show constitutively active CCaMK activity and/or LHK1 activity.
  • the foreign nucleic acid molecule does preferably not comprise a nucleotide sequence encoding a constitutively active CCaMK (DMI3 ortholog) and/or a nucleotide sequence encoding a constitutively active LHK1.
  • the foreign nucleic acid is preferably one described herein encoding a mutant CYCLOPS protein.
  • Further aspects of the present invention are:
  • a (mutant) nucleic acid molecule or the vector as described herein for the production of a plant, plant tissue or plant cell being capable of developing nodules, in particular root nodules, more preferably for developing spontaneously developing root nodules, preferably in the absence of rhizobia and/or rhizobial signal molecules.
  • a (mutant) nucleic acid molecule or the vector as described herein for the production of a plant, plant tissue or plant cell being capable of developing nodules, in particular root nodules, more preferably for developing spontaneously developing root nodules, preferably in the absence of rhizobia and/or rhizobial signal molecules.
  • Kit comprising a nucleic acid encoding a mutant CYCLOPS protein of the present invention, a vector comprising said nucleic acid and/or a plant of the present invention and rhizobia, preferably selected from at least one or more of the bacteria described herein after.
  • Rhizobia fall into two classes of the proteobacteria - the alpha- and beta-proteobacteria.
  • Alpha-proteobacteria include Rhizobiales.
  • Rhizobiales include Bradyrhizobiaceae (B.
  • Rhizobiaceae (Rhizobium sp., Sinorhizobium sp.). Most of the rhizobia belong to the order Rhizobiales but several rhizobia occur in distinct bacterial orders of the proteobacteria. Rhizobiales include Bradyrhizobiaceae and Rhizobiaceae.
  • Beta-proteobacteria include Burkholderiales.
  • Burkholderiales include Burkholderiaceae (Burkholderia sp.) and Oxalobacteraceae (Herbaspirillum sp.).
  • rhizobial bacteria preferably selected from at least one or more of those described above for the infection and/or colonization of a plant of the present invention, preferably of the root nodules formed by a plant of the present invention.
  • the antibody specifically binding to an epitope comprising the codon at a position corresponding to position 50 and/or 154 of the amino acid sequence of SEQ ID No:2, wherein said codon encodes an amino acid mimicking the effects of phosphorylation.
  • CYCLOPS contains in total 5 phosphorylation sites. Accordingly, it is an aspect of the present invention to provide a plant comprising a nucleotide sequence of a (mutant) CYCLOPS gene, wherein said nucleotide sequence comprises at one or more position(s), i.e., at one, two, three, four or five position(s) corresponding to a first position PN1 and/or a second position PN2 and/or a third position PN3 and/or a fourth position PN4 and/or a fifth position PN5, respectively, of the nucleotide sequence shown in SEQ ID No: 1 , a codon encoding an amino acid mimicking the effects of phosphorylation, wherein PN1 is nucleotides 40-42, PN2 is nucleotides 148-150, PN3 is nucleotides 460-462, PN4 is nucleotides 751-753 and PN5 is nucleotides 1234
  • the present invention provides a plant comprising a nucleotide sequence of a (mutant) CYCLOPS gene, wherein said nucleotide sequence comprises at
  • PN1 is nucleotides 40-42
  • PN2 is nucleotides 148-150
  • PN3 is nucleotides 460-462
  • PN4 is nucleotides 751-753
  • PN5 is nucleotides 1234-1236 of the nucleotide sequence shown in SEQ ID No: 1.
  • PN1 is nucleotides 40-42
  • PN2 is nucleotides 148-150
  • PN3 is nucleotides 460-462
  • PN4 is nucleotides 751-753
  • PN5 is nucleotides 1234-1236 of the nucleotide sequence shown in SEQ ID No: 1.
  • PN1 is nucleotides 40-42
  • PN2 is nucleotides 148-150
  • PN3 is nucleotides 460-462
  • PN4 is nucleotides 751-753
  • PN5 is nucleotides 1234-1236 of the nucleotide sequence shown in SEQ ID No: 1.
  • PN1 is nucleotides 40-42
  • PN2 is nucleotides 148-150
  • PN3 is nucleotides 460-462
  • PN4 is nucleotides 751-753
  • PN5 is nucleotides 1234-1236 of the nucleotide sequence shown in SEQ ID No: 1.
  • the present invention provides a plant comprising a nucleotide sequence of a (mutant) CYCLOPS gene, wherein said nucleotide sequence comprises at
  • PN1 is nucleotides 40-42
  • PN2 is nucleotides 148-150
  • PN3 is nucleotides 460-462
  • PN4 is nucleotides 751-753
  • PN5 is nucleotides 1234-1236 of the nucleotide sequence shown in SEQ ID No: 1.
  • position PN X (with X being 1 , 2, 3, 4 or 5)" means a nucleotide position within a specified SEQ ID No., in particular within a specified nucleotide sequence.
  • PN1 , PN2, PN3, PN4 and/or PN5" any possible combination (as illustrated in the first, second, third, fourth and fifth, respectively, aspect of the present invention) of codons as specified herein is meant.
  • PN1 when used herein is the codon at nucleotide position 40-42
  • PN2 is the codon at nucleotide position 148-150
  • PN3 is the codon at nucleotide position 460-462
  • PN4 is the codon at nucleotide position 751-753
  • PN5 is the codon at nucleotide position 1234-1236 of SEQ ID No:1.
  • the nucleotide sequence of a (mutant) CYCLOPS gene encodes a (mutant) CYCLOPS protein having an amino acid sequence which is at least 30%, preferably at least 40% or 50%, more preferably at least 60 or 70 %, even more preferably at least 80%, particular preferably at least 90% and even more particular preferably at least 95% identical to the amino acid sequence of SEQ ID No:2 and comprises at a position corresponding to a position PA1 , PA2, PA3, PA4 and/or PA5 of the amino acid sequence shown in SEQ ID No:2, as defined herein in the sixth, seventh, eighth, ninth and tenth aspect, respectively, an amino acid mimicking the effects of phosphorylation, wherein PA1 is amino acid 14, PA2 is amino acid 50, PA3 is amino acid 154, PA4 is amino acid 251 and PA5 is amino acid 412 of the amino acid sequence of SEQ ID No.2.
  • plants which comprise a CYCLOPS protein having at one or more position(s), i.e., at one, two, three, four or five position(s) corresponding to a first position PA1 and/or a second position PA2 and/or a third position PA3 and/or a fourth position PA4 and/or a fifth position PA5, respectively, of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2, an amino acid mimicking the effects of phosphorylation, wherein PA1 is amino acid 14, PA2 is amino acid 50, PA3 is amino acid 154, position PA4 is amino acid 251 and PA5 is amino acid 412.
  • the present invention provides a plant comprising a (mutant) CYCLOPS protein having at one or more position(s), i.e., at one, two, three, four or five position(s) corresponding to a first position PA1 and/or a second position PA2 and/or a third position PA3 and/or a fourth position PA4 and/or a fifth
  • PA1 is amino acid 14
  • PA2 is amino acid 50
  • PA3 is amino acid 154
  • PA4 is amino acid 251
  • PA5 is amino acid 412 of the amino acid sequence shown in SEQ ID No:2.
  • the present invention provides a plant comprising a (mutant) CYCLOPS protein having at least one of the following properties:
  • PA1 is amino acid 14
  • PA2 is amino acid 50
  • PA3 is amino acid 154
  • PA4 is amino acid 251
  • PA5 is amino acid 412 of the amino acid sequence shown in SEQ ID No:2.
  • the present invention provides a plant comprising a (mutant) CYCLOPS protein having at least one of the following properties:
  • PA1 is amino acid 14
  • PA2 is amino acid 50
  • PA3 is amino acid 154
  • PA4 is amino acid 251
  • PA5 is amino acid 412 of the amino acid sequence shown in SEQ ID No:2.
  • the present invention provides a plant comprising a (mutant) CYCLOPS protein having at at least
  • PA1 is amino acid 14
  • PA2 is amino acid 50
  • PA3 is amino acid 154
  • PA4 is amino acid 251
  • PA5 is amino acid 412 of the amino acid sequence shown in SEQ ID No:2.
  • the present invention provides a plant comprising a (mutant) CYCLOPS protein having at
  • PA1 is amino acid 14
  • PA2 is amino acid 50
  • PA3 is amino acid 154
  • PA4 is amino acid 251
  • PA5 is amino acid 412 of the amino acid sequence shown in SEQ ID No:2.
  • position PA X (with X being 1 , 2, 3, 4 or 5)” means an amino acid position within a specified SEQ ID No., in particular within a specified amino acid sequence.
  • PA1 , PA2, PA3, PA4 and/or PA5" any possible combination (as illustrated in the sixth, seventh, eighth, ninth and tenth, respectively, aspect of the present invention) of amino acids as specified herein is meant.
  • PA1 when used herein is the amino acid at position 14
  • PA2 is the amino acid at position 50
  • PA3 is the amino acid at position 154
  • PA4 is the amino acid at position 251
  • PA5 is the amino acid at position 412 of the amino acid sequence of SEQ ID No.2.
  • mutant/mutated allele refers to any one of the two groups.
  • mutant/mutated CYCLOPS allele refers to any one of the two groups.
  • mutant/mutated CYCLOPS gene refers to any one of the two groups.
  • nucleotide sequence which comprises at one, two, three, four or five, respectively, position(s) corresponding to position PN1 , PN2, PN3, PN4 and/or PN5, respectively, as defined herein of the nucleotide sequence shown in SEQ ID No:1 a codon encoding an amino acid mimicking the effects of phosphorylation, or
  • mutant/mutated CYCLOPS protein/polypeptide or “variant CYCLOPS protein/polypeptide” are used interchangeably in the context of the still further aspects and refer to
  • a CYCLOPS protein having at one, two, three, four or five, respectively, position(s) corresponding to position PA1 , PA2, PA3, PA4 and/or PA5, respectively, as defined herein, of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation, or
  • a CYCLOPS protein encoded by a nucleotide sequence which comprises at one, two, three, four or five, respectively, position(s) corresponding to position PN1 , PN2, PN3, PN4 and/or PN5, respectively, as defined herein, of the nucleotide sequence shown in SEQ ID No:1 a codon encoding an amino acid mimicking the effects of phosphorylation.
  • wild-type allele In contrast, unless indicated otherwise, the terms “wild-type allele,” “wild-type CYCLOPS allele,” or “wild-type CYCLOPS gene” refer to
  • nucleotide sequence which does not comprise at one, two, three, four or five, respectively, position(s) corresponding to position PN1 , PN2, PN3, PN4 and/or PN5, respectively, as defined herein, of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid mimicking the effects of phosphorylation, or
  • nucleotide sequence that encodes a CYCLOPS protein which does not have at one, two, three, four or five, respectively, position(s) corresponding to position PA1 , PA2, PA3, PA4 and/or PA5, respectively, as defined herein, of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation.
  • a "wild-type CYCLOPS gene” has at a position corresponding to position PN1 , PN2, PN3, PN4 and PN5, respectively, as defined herein of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid which is capable of being phosphorylated, such as serine, threonine or tryptophane, with tryptophane being less preferred.
  • the codon at position PN1 , PN2, PN3, PN4 and/or PN5 does not encode an aspartate or glutamate.
  • wild-type allele may, or may not, comprise mutations, other than the mutations at PN1 and/or PN2 and/or PN3 and/or PN4 and/or PN5 as defined herein.
  • wild-type CYCLOPS protein/polypeptide are used interchangeably when used in the context of the still further aspects and refer to
  • a CYCLOPS protein which does not have at one, two, three, four or five, respectively, position(s) corresponding to position PA1 , PA2, PA3, PA4 and/or PA5, respectively, as defined herein, of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation, or
  • a CYCLOPS protein encoded by a nucleotide sequence which does not comprise at one, two, three, four or five, respectively, position(s) corresponding to position PN1 , PN2, PN3, PN4 and/or PN5, respectively, as defined herein, of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid mimicking the effects of phosphorylation.
  • amino acid at position PA1 , PA2, PA3, PA4 and/or PA5 is not an aspartate or glutamate.
  • a wild-type CYCLOPS protein has at one, two, three, four or five, respectively, position(s) corresponding to position PA1 , PA2, PA3, PA4 and/or PA5, respectively, as defined herein of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid which is capable of being phosphorylated, such as serine, threonine or tyrosine, with tyrosine being less preferred.
  • a preferred wild-type CYCLOPS protein is shown in SEQ ID No:2.
  • a plant of the present invention comprises a codon encoding an amino acid which mimicks the effects of phosphorylation.
  • the plant of the present invention comprises a codon encoding an amino acid which mimicks the effects of phosphorylation.
  • said phosphorylation mimicking amino acid is preferably an acidic amino acid, preferably glutamate or aspartate.
  • amino acid(s) that is/are preferably phosphorylated by CCaMK is/are one or more serine(s) and/or threonine(s) comprised by a CYCLOPS protein, more preferably it is the serine residue in a CYCLOPS protein at a position corresponding to position 14, 50, 154, 251 and/or 412 of the amino acid sequence shown in SEQ ID No:2.
  • the amino acid mimicking the effect(s) of phosphorylation is preferably homolog, variant or the like of aspartic acid or glutamic acid which can be used in chemical synthesis of proteins, more preferably it is an acidic amino acid, even more preferably it is aspartate (Asp or D) or glutamate (Glu or E).
  • the amino acid at a position corresponding to position 14, 50, 154, 251 and/or 412 of the amino acid sequence of SEQ ID No:2 is different from serine in a (mutant) CYCLOPS protein of the present invention.
  • a (mutant) CYCLOPS gene of the present invention encodes a protein comprising any one of the mutations/substitutions specified herein, for example, in the sixth, seventh, eighth, ninth and tenth aspect, respectively.
  • the S(PA1 , PA2, PA3, PA4 and/or PA5)D or S(PA1 , PA2, PA3, PA4 and/or PA5)E substitution is a result of an alteration of the codon at a position corresponding to position PN1 , PN2, PN3, PN4 and/or PN5, respectively, of the nucleotide sequence shown in SEQ ID No: 1.
  • a S(PA1 , PA2, PA3, PA4 and/or PA5)D or S(PA1 , PA2, PA3, PA4 and/or PA5)E substitution is a result of an alteration of the codon at a position corresponding to position 40-42, 148-150, 460-462, 751-753 and/or 1234-1236, respectively, of the nucleotide sequence shown in SEQ ID No: 1 so that said codon encodes an amino acid mimicking the effects of phosphorylation such as an acidic amino acid, more preferably aspartate or glutamate, respectively ("D” is encoded by the codon "GAC” or "GAT", ⁇ " is encoded by the codon "GAG” or "GAA” at said position).
  • nucleotides/amino acids may differ in the indicated number but may still have similar neighboring nucleotides/amino acids. Said nucleotides/amino acids which may be exchanged, deleted or added are also comprised by the term "corresponding position”.
  • the skilled person may, when aligning the reference sequence (subject sequence) SEQ ID No: 1 or 2 with a nucleotide or amino acid sequence of interest (query sequence), for example, inspect a sequence of interest for the sequence motif RXXS (or the corresponding nucleotide sequence encoding this motif, respectively) when looking for the amino acid position (or codon encoding the amino acid at said position) as specified herein, i.e., a position corresponding to position PA1 , PA2, PA3, PA4 and/or PA5 of the amino acid sequence shown in SEQ ID No:2 or a position corresponding to position PN1 , PN2, PN3, PN4 and/or PN5 of the nucleotide sequence shown in SEQ ID No: 1 , respectively.
  • the "S” of said motif is subject to phosphorylation by a DMI3 protein such as CCaMK. Said “S” is then replaced in a mutant CYCLOPS protein by an amino acid mimicking the effects of phosphorylation.
  • the term "position 148-150 of the nucleotide sequence shown in SEQ ID No: 1" and/or the term “position 460-462 of the nucleotide sequence shown in SEQ ID No: 1” is to be replaced by the term "position PN1 , PN2, PN3, PN4 and/or PN5", wherein PN1 is nucleotides 40-42, PN2 is nucleotides 148-150, PN3 is nucleotides 460-462, PN4 is nucleotides 751-753 and PN5 is nucleotides 1234-1236 of the nucleotide sequence shown in SEQ ID No: 1
  • the term "position 50 of the amino acid sequence shown in SEQ I D No:2" and/or the term “position 154 of the amino acid sequence shown in SEQ ID No:2” is to be replaced by the term "position PA1 , PA2, PA3, PA4 and/or PA5", wherein PA1 is amino acid 14, PA2 is amino acid 50, PA3 is amino acid 154, PA4 is amino acid 251 and PA5 is amino acid 412 of the amino acid sequence shown in SEQ ID No:2.
  • the invention may also be characterized by the following items: 1.
  • a plant comprising a nucleotide sequence of a (mutant) CYCLOPS gene, wherein said nucleotide sequence comprises at a first position corresponding to position 148- 150 of the nucleotide sequence shown in SEQ ID No:1 and/or at a second position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid mimicking the effects of phosphorylation.
  • nucleotide sequence is integrated in the genome of said plant.
  • nucleotide sequence of a CYCLOPS gene encodes a (mutant) CYCLOPS protein having an amino acid sequence which is at least 30% identical to the amino acid sequence of SEQ ID No:2 and which has at a first position corresponding to position 50 of the amino acid sequence shown in SEQ ID No: 2 and/or at a second position corresponding to position 154 of the amino acid sequence shown in SEQ ID No: 2 an amino acid mimicking the effects of phosphorylation.
  • amino acid mimicking the effects of phosphorylation is an acidic amino acid, preferably gulamate or aspartate.
  • the plant of any one of the preceding items which is a non-legume plant.
  • the plant of any one of the preceding items which is a non-legume crop plant.
  • the plant of item 1 1 wherein said plant comprises in the nucleotide sequence of at least one CYCLOPS gene in its endogenous gene locus, a first codon encoding an amino acid mimicking the effects of phosphorylation at a position corresponding to position 148-150 of the nucleotide sequence of the CYCLOPS gene shown in SEQ ID No: 1 and/or at a second codon encoding an amino acid mimicking the effects of phosphorylation at a position corresponding to position 460-462 of the nucleotide sequence of the CYCLOPS gene shown in SEQ ID No: 1.
  • CYCLOPS protein shown in SEQ ID No:2 and/or at a second position corresponding to position 154 of the amino acid sequence of the CYCLOPS protein shown in SEQ ID No:2 an amino acid mimicking the effects of phosphorylation. 14. Plant of any one of the preceding items, which is agronomical exploitable.
  • a nucleic acid comprising the nucleotide sequence of a CYCLOPS gene, wherein said nucleotide sequence comprises at a first position corresponding to position 148- 150 of the nucleotide sequence shown in SEQ ID No:1 and/or at a second position corresponding to position 460-463 of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid mimicking the effects of phosphorylation.
  • nucleic acid of item 16 wherein said nucleotide sequence is selected from the group consisting of:
  • nucleotide sequence having at least 30% identity to the nucleotide sequence shown in SEQ ID No: 1 and having at a first position corresponding to position 148-150 of the nucleotide sequence shown in SEQ ID No:1 and/or at a second position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No: 1 a codon encoding an amino acid mimicking the effects of phosphorylation, said nucleotide sequence encodes a CYCLOPS protein;
  • nucleotide sequence encoding the polypeptide shown in SEQ ID No:4; and (e) a fragment of the nucleotide sequence of (a), (b), (c) or (d), wherein the nucleotide sequence comprised by said fragment has at a first position corresponding to position 148-150 of the nucleotide sequence shown in SEQ ID No: 1 and/or at a second position corresponding to position 460-462 of the nucleotide sequence shown in SEQ ID No:1 a codon encoding an amino acid mimicking the effects of phosphorylation, said fragment encodes a CYCLOPS protein, or
  • a vector comprising the nucleic acid molecule of item 16 or 17.
  • the vector of item 18, wherein said nucleic acid molecule is operatively linked with an expression control sequence.
  • the vector of item 18 or 19, wherein said nucleic acid molecule comprises at its 3'- end a termination signal sequence.
  • a (genetically engineered) host cell comprising the nucleic acid molecule of item 16 or 17 or the vector of any one of items 18-20.
  • the host cell of item 21 which is a plant cell.
  • a plant cell obtainable according to the method of item 24.
  • a method for the production of a plant being capable of spontaneously developing nodules in the absence of rhizobia and/or rhizobial signal molecules and in the absence of CCAMK activity and/or LHK1 activity, comprising transforming a plant with a foreign nucleic acid molecule the presence or expression of which in the cells of said plant results in the spontaneous development of nodules in the absence of rhizobia.
  • nucleic acid molecule of item 16 or 17 or the vector of any one of items 18- 20 for the production of a plant, plant tissue or plant cell being capable of spontaneously developing nodules in the absence of rhizobia.
  • Kit comprising the nucleic acid of item 16 or 17, the vector of any one of items 18-20 and/or a plant of any one of items 1-14 and one or more rhizobial bacteria, preferably selected from those described herein.
  • S251 and S412 are located in the sequence motif RXX S (indicated in green/red). Nuclear localization signals (NLS) and coiled coil domain are marked in bold and underlined.
  • Figure 2
  • AM symbiosis was scored positive, if arbuscules were formed within root cortical cells (visualized by ink staining of AM structures). Transformed plants were identified by visually scoring the fluorescence of the transformation marker GFP. Scale bar M. loti inoculated plants 1 mm, Scale bar AM stain 200 ⁇ . Figure 3
  • CYCLOPS-S50DS154D induces spontaneous nodules independent of kinase active CCaMK.
  • CYCLOPS-S50DS154D equipped with the endogenous promoter (pCyclops) was introduced into the ccamk-3 mutant background and plants were inoculated with Glomus intraradices, or M. loti DsRed, while part of the plants was left un-inoculated. After 5 weeks, plants were scored for symbiosis formation. In all conditions tested, CYCLOPS-S50DS154D induced nodule organogenesis, but nodules were not infected with rhizobia. Further, AM was not formed. Scale bars 0.5 mm. Figure 5
  • CYCLOPS genomic sequence was amplified by polymerase chain reaction (Sambrook et al., cited herein) using primer "N-term sym30" (5 ' -CACCATGGAAGGGAGGGGG-3) (SEQ ID No:5) and "C-term sym30” (5 ' -TTACATTTTTTCAGTTTCTGATAGAATTC-3) (SEQ ID No:6) using Plasmid J18 (containing Lotus japonicus genomic CYCLOPS sequence, cloned from Lotus japonicus Gifu wildtype genomic DNA, (unpublished); www.
  • CYCLOPS native promoter was amplified with primers CEW7 (5 ' -CAC CCC AAA CTA TCA GGT CAA GTC TGC-3 ' ) (SEQ ID No:7) and CEW8 (5 ' -TCA AAG TCG ACG TTT GGC TCA ACA GCA CTT TC-3 ' ) (SEQ ID No:8) using J30 (unpublished) as template, containing native CYCLOPS promoter (2435 bp) cloned from Lotus japonicus Gifu wildtype genomic DNA). After removal of the 35S promoter, the CYCLOPS promoter was cloned into the binary vector pK7WG2D (Karimi et al. (2002), Trends Plant Sci 7, 193-195) yielding vector "pCYCLOPSpromoterWG2D".
  • polymerase chain mutagenesis reaction was carried out using plasmid pCEW416 as template and primer pairs SY36 (5 ' - CTTTCGCGCAGATGACGAGGAGCTTTTC-3 ' ) (SEQ ID No:9) and SY37 (5 ' - GAAAAGCTCCTCGTCATCTGCGCGAAAG-3 ' ) (SEQ ID No: 10) to generate mutation S50D, resulting in plasmid pCEW416-S50D.
  • a second polymerase chain mutagenesis reaction was carried out on template pCEW416- S50D to generate S154D (corresponding to nucleotides 460-462 of the CYCLOPS coding sequence), whereby nucleotide triplet TCC encodes serine and GAC encodes aspartate) by using primer pairs SY42 (5 ' -GACAAGAAGCCGGGACTCTGAATTGCGGTAC-3 ' ) (SEQ ID No:1 1) and SY43 (5 ' -GTACCGCAATTCAGAGTCCCGGCTTCTTGTC-3 ' ) (SEQ ID No:12).
  • SY42 5 ' -GACAAGAAGCCGGGACTCTGAATTGCGGTAC-3 '
  • SY43 5 ' -GTACCGCAATTCAGAGTCCCGGCTTCTTGTC-3 '
  • the resulting plasmid was named pCEW416-S50DS154D.
  • the mutated genomic CYCLOPS sequence 3xHA-CYCLOPS- S50DS154D was then recombined into the plasmid pCYCLOPSpromoterWG2D by LR reaction resulting in the vector pCYCLOPS:HAgCYCLOPS-S50DS154D.
  • Correct orientation (3 ' to the CYCLOPS promoter) and correct nucleotide sequence of S50D and S154D mutated genomic CYCLOPS was verified by sequencing of pCYCLOPS.HAgCYCLOPS- S50DS154D.
  • pCYCLOPS:HAgCYCLOPS-S50DS154D was transformed into A. Rhizogenes strain AR1 193 (Stougaard et al. (1987), Mol Gen Genet 207, 251-255) by electroporation. Transformation of pCYCLOPS:HAgCYCLOPS-S50DS154D into AR1 193 was verified by colony PCR. In order to examine the effect of expression of pCYCLOPS:gCYCLOPS-S50DS154D in planta, the construct was transformed into the L. japonicus cyclops-3 and ccamk-3 mutant background (Perry et al. (2009), Plant Physiol 151 , 1281-1291) by hairy root transformation (Diaz et al. (2005), In: Lotus japonicus Handbook. arquez AJ, editor. Dordrecht, The Netherlands: Springer, 261-277.
  • Transformation of roots was verified by visualizing the transformation marker GFP.
  • Transformed roots were either, incubated sterile for 8 weeks post transformation, inoculated for 5 weeks with Mesorhizobium loti Maff303099 expressing Dsred fluorescent protein (Maekawa et al. (2009), Plant J. 58, 183-194), or inoculated for 5 weeks with Glomus intraradices.
  • Restoration of root nodule symbiosis in transformed mutant plant roots by M. loti was scored positive, if infected nodules (visualized by DsRed expressing M. loti bacteria) were observed.
  • CYCLOPS-S50DS154D induces spontaneous nodules independent of kinase active CCaMK.
  • CYCLOPS-S50DS154D equipped with the endogenous promoter (pCyclops) was introduced into the ccamk-3 mutant background and plants were inoculated with Glomus intraradices, or M. loti DsRed, while part of the plants was left un-inoculated. After 5 weeks, plants were scored for symbiosis formation. In all conditions tested, CYCLOPS-S50DS154D induced nodule organogenesis, but nodules were not infected with rhizobia. Further, AM was not formed (see Figure 4).

Abstract

La présente invention concerne une plante qui comprend une séquence nucléotide d'un gène CYCLOPS (mutant), ladite séquence nucléotide comportant ‑ à une première position correspondant à la position 148 à 150 de la séquence nucléotide, représentée dans la SEQ ID n° 1, et/ou à une seconde position correspondant à la position 460 à 462 de la séquence nucléotide, représentée dans la SEQ ID n° 1 ‑ un codon codant pour un acide aminé, imitant les effets de la phosphorylation. Par ailleurs, l'invention porte sur des plantes qui comprennent une protéine CYCLOPS possédant ‑ à une première position correspondant à la position 50 de la séquence d'acide aminé de la protéine CYCLOPS, représentée dans la SEQ ID n° 2, et/ou à une seconde position correspondant à la position 154 de la séquence d'acide aminé de la protéine CYCLOPS, représentée dans la SEQ ID n° 2 ‑ un acide aminé imitant les effets de la phosphorylation. Les plantes de la présente invention sont aptes à développer des nodules de racine, de préférence des nodules se développant spontanément, de préférence en l'absence de signal rhizobium et/ou de molécules de signal rhizobien.
PCT/EP2011/065070 2010-09-02 2011-09-01 Organogenèse spontanée dans des plantes WO2012028673A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10175084 2010-09-02
EP10175084.2 2010-09-02
EP10175012A EP2426204A1 (fr) 2010-09-02 2010-09-02 Organogenèse spontanée de nodules dans les plantes
EP10175012.3 2010-09-02

Publications (1)

Publication Number Publication Date
WO2012028673A1 true WO2012028673A1 (fr) 2012-03-08

Family

ID=45772193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/065070 WO2012028673A1 (fr) 2010-09-02 2011-09-01 Organogenèse spontanée dans des plantes

Country Status (1)

Country Link
WO (1) WO2012028673A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015192566A1 (fr) * 2014-06-16 2015-12-23 北京市农林科学院 Gène cca de résistance à la corynesporiose du concombre ainsi que marqueurs moléculaires liés et leurs applications
WO2018236792A1 (fr) * 2017-06-21 2018-12-27 North Carolina State University Ré-ingénierie de la symbiose mycorhizienne chez les plantes

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565350A (en) 1993-12-09 1996-10-15 Thomas Jefferson University Compounds and methods for site directed mutations in eukaryotic cells
US5731181A (en) 1996-06-17 1998-03-24 Thomas Jefferson University Chimeric mutational vectors having non-natural nucleotides
US5760012A (en) 1996-05-01 1998-06-02 Thomas Jefferson University Methods and compounds for curing diseases caused by mutations
US5780296A (en) 1995-01-17 1998-07-14 Thomas Jefferson University Compositions and methods to promote homologous recombination in eukaryotic cells and organisms
WO1998049350A1 (fr) 1997-04-30 1998-11-05 Regents Of The University Of Minnesota Utilisation in vivo d'oligonucleobases recombinagenes pour corriger les lesions genetiques des hepatocytes
WO1999007865A1 (fr) 1997-08-05 1999-02-18 Kimeragen, Inc. Utilisation d'oligonucleotides a double helice melanges pour effectuer des modifications genetiques localisees dans des plantes
US5888983A (en) 1996-05-01 1999-03-30 Thomas Jefferson University Method and oligonucleobase compounds for curing diseases caused by mutations
WO1999040789A1 (fr) 1998-02-12 1999-08-19 Regents Of The University Of Minnesota Procedes et composes pour le traitement genetique de l'hyperlipidemie
WO1999058702A1 (fr) 1998-05-12 1999-11-18 Kimeragen, Inc. Chimeraplastie acellulaire et utilisation eucaryote de vecteurs heteroduplex mutationnels
WO1999058723A1 (fr) 1998-05-12 1999-11-18 Kimeragen, Inc. Vecteurs heteroduplex mutationnels et leur utilisation dans les bacteries
US6271360B1 (en) 1999-08-27 2001-08-07 Valigen (Us), Inc. Single-stranded oligodeoxynucleotide mutational vectors
EP1198985A1 (fr) 1999-07-22 2002-04-24 Japan as represented by Dir. Gen. of National Inst. of Agrobiological Resources,Ministry of Agriculture, Forestry and Fisherie Procede de transformation ultrarapide de monocotyledon
US6870075B1 (en) 1999-10-07 2005-03-22 Valigen (Us), Inc. Methods of making non-transgenic herbicide resistant plants
WO2007006318A2 (fr) * 2005-07-14 2007-01-18 Aarhus Universitet Nodulation spontanee dans des plantes

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756325A (en) 1993-12-09 1998-05-26 Thomas Jefferson University Compounds and methods for site directed mutations in eukaryotic cells
US5871984A (en) 1993-12-09 1999-02-16 Thomas Jefferson University Compounds and methods for site directed mutations in eukaryotic cells
US5565350A (en) 1993-12-09 1996-10-15 Thomas Jefferson University Compounds and methods for site directed mutations in eukaryotic cells
US5780296A (en) 1995-01-17 1998-07-14 Thomas Jefferson University Compositions and methods to promote homologous recombination in eukaryotic cells and organisms
US5945339A (en) 1995-01-17 1999-08-31 Cornell Research Foundation, Inc. Methods to promote homologous recombination in eukaryotic cells and organisms
US5760012A (en) 1996-05-01 1998-06-02 Thomas Jefferson University Methods and compounds for curing diseases caused by mutations
US5888983A (en) 1996-05-01 1999-03-30 Thomas Jefferson University Method and oligonucleobase compounds for curing diseases caused by mutations
US5731181A (en) 1996-06-17 1998-03-24 Thomas Jefferson University Chimeric mutational vectors having non-natural nucleotides
US5795972A (en) 1996-06-17 1998-08-18 Thomas Jefferson University Chimeric mutational vectors having non-natural nucleotides
WO1998049350A1 (fr) 1997-04-30 1998-11-05 Regents Of The University Of Minnesota Utilisation in vivo d'oligonucleobases recombinagenes pour corriger les lesions genetiques des hepatocytes
US7094606B2 (en) 1997-08-05 2006-08-22 Arntzen Charles J Use of mixed duplex oligonucleotides to effect localized genetic changes in plants
WO1999007865A1 (fr) 1997-08-05 1999-02-18 Kimeragen, Inc. Utilisation d'oligonucleotides a double helice melanges pour effectuer des modifications genetiques localisees dans des plantes
WO1999040789A1 (fr) 1998-02-12 1999-08-19 Regents Of The University Of Minnesota Procedes et composes pour le traitement genetique de l'hyperlipidemie
WO1999058723A1 (fr) 1998-05-12 1999-11-18 Kimeragen, Inc. Vecteurs heteroduplex mutationnels et leur utilisation dans les bacteries
US6004804A (en) 1998-05-12 1999-12-21 Kimeragen, Inc. Non-chimeric mutational vectors
US6010907A (en) 1998-05-12 2000-01-04 Kimeragen, Inc. Eukaryotic use of non-chimeric mutational vectors
WO1999058702A1 (fr) 1998-05-12 1999-11-18 Kimeragen, Inc. Chimeraplastie acellulaire et utilisation eucaryote de vecteurs heteroduplex mutationnels
EP1198985A1 (fr) 1999-07-22 2002-04-24 Japan as represented by Dir. Gen. of National Inst. of Agrobiological Resources,Ministry of Agriculture, Forestry and Fisherie Procede de transformation ultrarapide de monocotyledon
US6271360B1 (en) 1999-08-27 2001-08-07 Valigen (Us), Inc. Single-stranded oligodeoxynucleotide mutational vectors
US6479292B1 (en) 1999-08-27 2002-11-12 Valigen (Us), Inc. Genetic alteration in plants using single-stranded oligodeoxynucleotide vectors
US6870075B1 (en) 1999-10-07 2005-03-22 Valigen (Us), Inc. Methods of making non-transgenic herbicide resistant plants
WO2007006318A2 (fr) * 2005-07-14 2007-01-18 Aarhus Universitet Nodulation spontanee dans des plantes

Non-Patent Citations (75)

* Cited by examiner, † Cited by third party
Title
"Nucleic acid hybridization, a practical approach", 1985, IRL PRESS OXFORD
ALDEMITA, HODGES, PLANTA, vol. 199, 1996, pages 612 - 617
ALTSCHUL, J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL, J. MOL. EVOL., vol. 36, 1993, pages 290 - 300
ALTSCHUL, NUCL. ACIDS RES, vol. 25, 1997, pages 3389 - 3402
AUSUBEL: "Current Protocols in Molecular Biology", 1989, GREEN PUBLISHING ASSOCIATES AND WILEY INTERSCIENCE
B. JENES ET AL.: "Transgenic Plants, Vol. 1 , Engineering and Utilization", vol. 1, 1993, ACADEMIC PRESS, article "Techniques for Gene Transfer", pages: 128 - 143
BECHTHOLD, N, C R ACAD SCI PARIS LIFE SCI, vol. 316, 1993, pages 1194 - 1199
BEETHAM ET AL., PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 8774 - 8778
BOCK: "Transgenic plastids in basic research and plant biotechnology", J MOL BIOL., vol. 312, no. 3, 21 September 2001 (2001-09-21), pages 425 - 438, XP002206098, DOI: doi:10.1006/jmbi.2001.4960
CAPOEN WARD ET AL: "How CYCLOPS keeps an eye on plant symbiosis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 105, no. 51, December 2008 (2008-12-01), pages 20053 - 20054, XP002618637, ISSN: 0027-8424 *
CHAN ET AL., PLANT MOL BIOL, vol. 22, no. 3, 1993, pages 491 - 506
CHANG, PLANT J., vol. 5, 1994, pages 551 - 558
CHARPENTIER ET AL., PLANT CELL, vol. 20, 2009, pages 3467 - 3479
CLOUGH, BENT, PLANT J., vol. 16, 1998, pages 735 - 743
CLOUGH, SJ, BENT AF, THE PLANT J., vol. 16, 1998, pages 735 - 743
CROSSWAY A ET AL., MOL. GEN GENET, vol. 202, 1986, pages 179 - 185
DIAZ ET AL.: "Lotus japonicus Handbook", 2005, SPRINGER, pages: 261 - 277
DONG ET AL., PLANT CELL REP, vol. 25, 2006, pages 457 - 465
F. F. WHITE: "Transgenic Plants, Vol. 1 , Engineering and Utilization", vol. 1, 1993, ACADEMIC PRESS, article "Vectors for Gene Transfer in Higher Plants", pages: 15 - 38
FELDMAN, KA, MARKS MD, MOL GEN GENET, vol. 208, 1987, pages 274 - 289
FELDMANN ET AL.: "Arabidopsis", 1994, COLD SPRING HARBOR LABORATORY PRESS, pages: 137 - 172
FELDMANN K: "Methods in Arabidopsis Research", 1992, WORD SCIENTIFIC, SINGAPORE, pages: 274 - 289
FERGUSON BRETT J ET AL: "Molecular Analysis of Legume Nodule Development and Autoregulation", JOURNAL OF INTEGRATIVE PLANT BIOLOGY, vol. 52, no. 1, January 2010 (2010-01-01), pages 61 - 76, XP002618638, ISSN: 1672-9072 *
FRAME ET AL., PLANT PHYSIOL, vol. 129, no. 1, 2002, pages 13 - 22
GLEASON CYNTHIA ET AL: "Nodulation independent of rhizobia induced by a calcium-activated kinase lacking autoinhibition", NATURE (LONDON), vol. 441, no. 7097, June 2006 (2006-06-01), pages 1149 - 1152, XP002618635, ISSN: 0028-0836 *
GRIMSRUD ET AL., PLANT PHYSIOL., vol. 152, 2010, pages 19 - 28
GRIMSRUD PAUL A ET AL: "Large-Scale Phosphoprotein Analysis in Medicago truncatula Roots Provides Insight into in Vivo Kinase Activity in Legumes", PLANT PHYSIOLOGY (ROCKVILLE), vol. 152, no. 1, January 2010 (2010-01-01), pages 19 - 28, XP002618640, ISSN: 0032-0889 *
GROTH ET AL., PLANT CELL, vol. 22, 2010, pages 2509 - 2526
HAYASHI ET AL., PLANT J., vol. 63, 2010, pages 141 - 154
HAYASHI ET AL., SCIENCE, 1992, pages 1350 - 1353
HAYASHI TERUYUKI ET AL: "A dominant function of CCaMK in intracellular accommodation of bacterial and fungal endosymbionts", PLANT JOURNAL, vol. 63, no. 1, July 2010 (2010-07-01), pages 141 - 154, XP002618639, ISSN: 0960-7412 *
HIEI ET AL., PLANT J, vol. 6, no. 2, 1994, pages 271 - 282
HOFGEN, WILLMITZER, NUCL. ACID RES., vol. 16, 1988, pages 9877
ISHIDA ET AL., NAT. BIOTECHNOL, vol. 14, no. 6, 1996, pages 745 - 750
KANAMORI ET AL., PROC NATL ACAD SCI USA, vol. 103, 2006, pages 359 - 364
KARIMI ET AL., TRENDS PLANT SCI, vol. 7, 2002, pages 193 - 195
KATAVIC, MOL GEN GENET, vol. 245, 1994, pages 363 - 370
KLAUS ET AL., NATURE BIOTECHNOLOGY, vol. 22, no. 2, 2004, pages 225 - 229
KLEIN TM ET AL., NATURE, vol. 327, 1987, pages 70
KOCHEVENKO, WILLMITZER, PLANT PHYSIOLOGY, vol. 132, 2003, pages 174 - 184
KRENS, F.A. ET AL., NATURE, vol. 296, 1982, pages 72 - 74
LIGHTNER J, CASPAR T: "Methods on Molecular Biology", vol. 82, 1998, HUMANA PRESS, pages: 91 - 104
MADSEN ET AL., NATURE, vol. 425, 2003, pages 637 - 640
MAEKAWA ET AL., PLANT J., vol. 58, 2009, pages 183 - 194
MAIT, TRANSGENIC RESEARCH, vol. 6, 1997, pages 143 - 156
MALIGA, P: "Progress towards commercialization of plastid transformation technology", TRENDS BIOTECHNOL., vol. 21, 2003, pages 20 - 28, XP004397633, DOI: doi:10.1016/S0167-7799(02)00007-0
MARKMANN ET AL., PLOS BIOL., vol. 6, 2008, pages E68
MCCALLUM ET AL., NAT BIOTECHNOL, vol. 18, 2000, pages 455 - 457
MESSINESE ET AL., MOL PLANT MICROBE INTERACT., vol. 8, 2007, pages 912 - 921
NEGRUTIU I ET AL., PLANT MOL BIOL, vol. 8, 1987, pages 363 - 373
NI, PLANT JOURNAL, vol. 7, 1995, pages 661 - 676
OKUZAKI, TORIYAMA, PLANT CELL REP, vol. 22, 2004, pages 509 - 512
OLDROYD, DOWNIE, NATURE REVIEWS, vol. 5, 2004, pages 566 - 576
PERRY ET AL., PLANT PHYSIOL, vol. 151, 2009, pages 1281 - 1291
POTRYKUS, ANNU. REV. PLANT PHYSIOL. PLANT MOLEC. BIOL., vol. 42, 1991, pages 205 - 225
QING QU, TAKAIWA, PLANT BIOTECHNOL. J., vol. 2, 2004, pages 113 - 125
RADUTOIU ET AL., NATURE, vol. 425, 2003, pages 585 - 592
REDEI GP AND KONCZ C: "Methods in Arabidopsis Research", 1992, SINGAPORE, WORLD SCIENTIFIC PUBLISHING CO, pages: 16 - 82
SAITO ET AL., PLANT CELL, 2007
SAMBROOK, RUSSELL: "Molecular Cloning, A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY
SHILLITO R. D. ET AL., BIO/TECHNOL, vol. 3, 1985, pages 1099 - 1102
STEMPLE, NAT REV GENET, vol. 5, 2004, pages 145 - 150
STOUGAARD ET AL., MOL GEN GENET, vol. 207, 1987, pages 251 - 255
TATUSOV, R. L. ET AL., SCIENCE, vol. 278, 1997, pages 631 - 637
TIRICHINE ET AL., NATURE, vol. 441, 2006, pages 1153 - 1156
TIRICHINE ET AL., SCIENCE, vol. 315, 2007, pages 104 - 107
TIRICHINE LEILA ET AL: "A gain-of-function mutation in a cytokinin receptor triggers spontaneous root nodule organogenesis", SCIENCE (WASHINGTON D C), vol. 315, no. 5808, January 2007 (2007-01-01), pages 104 - 107, XP002618633, ISSN: 0036-8075 *
TIRICHINE LEILA ET AL: "Deregulation of a Ca2+/calmodulin-dependent kinase leads to spontaneous nodule development", NATURE (LONDON), vol. 441, no. 7097, June 2006 (2006-06-01), pages 1153 - 1156, XP002618634, ISSN: 0028-0836 *
VIERHEILIG ET AL., APPL ENVIRON MICROBIOL, vol. 64, 1998, pages 5004 - 5007
WANG ET AL., NEW PHYTOLOGIST, vol. 186, 2010, pages 514 - 525
YANO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 105, 2008, pages 20540 - 20545
YANO KOJI ET AL: "CYCLOPS, a mediator of symbiotic intracellular accommodation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 105, no. 51, December 2008 (2008-12-01), pages 20540 - 20545, XP002618636, ISSN: 0027-8424 *
ZHU ET AL., NAT. BIOTECHNOL., vol. 18, 2000, pages 555 - 558
ZHU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 8768 - 8773

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015192566A1 (fr) * 2014-06-16 2015-12-23 北京市农林科学院 Gène cca de résistance à la corynesporiose du concombre ainsi que marqueurs moléculaires liés et leurs applications
WO2018236792A1 (fr) * 2017-06-21 2018-12-27 North Carolina State University Ré-ingénierie de la symbiose mycorhizienne chez les plantes
US11248235B2 (en) 2017-06-21 2022-02-15 North Carolina State University Re-engineering of mycorrhizal symbiosis in plants

Similar Documents

Publication Publication Date Title
CN107164347B (zh) 控制水稻茎秆粗度、分蘖数、穗粒数、千粒重和产量的理想株型基因npt1及其应用
US9663794B2 (en) Heat-resistance rice gene OsZFP, screening marker and separation method thereof
CN107602681B (zh) 水稻粒宽基因gw5l及其应用
CN105916989A (zh) 大豆u6聚合酶iii启动子及其使用方法
CN106148390B (zh) Chy锌指蛋白转录激活辅因子及其应用
CHEN et al. Genetic transformation of rice with Pi-d2 gene enhances resistance to rice blast fungus Magnaporthe oryzae
CN110527695A (zh) 一种用于基因定点突变的核酸构建物
CN114423867A (zh) 改善种子大小和质量的方法
CN108864266A (zh) 一种与水稻落粒性及粒型相关的蛋白ssh1及其编码基因与应用
MX2008012443A (es) Genes de maiz para controlar el crecimiento y tamaño de organos en plantas y su uso en la mejora de plantas de cultivo.
CN110713994B (zh) 一种植物耐逆性相关蛋白TaMAPK3及其编码基因和应用
CN113061171B (zh) 抗稻瘟病蛋白和基因、分离的核酸及其应用
CN109971766A (zh) 一种与植物耐逆相关蛋白PwRBP1及其编码基因与应用
AU2014352999B2 (en) Nucleotide sequence encoding WUSCHEL-related homeobox4 (WOX4) protein from Corchorus olitorius and Corchorus capsularis and methods of use for same
CN112011557B (zh) 一种水稻基因OsRMT1及其在制备具有高温胁迫耐性转基因植物中的用途
US20170183680A1 (en) Dominant negative mutant krp-related proteins (krp) in zea mays and methods of their use
AU2014352999A1 (en) Nucleotide sequence encoding WUSCHEL-related homeobox4 (WOX4) protein from Corchorus olitorius and Corchorus capsularis and methods of use for same
WO2012028673A1 (fr) Organogenèse spontanée dans des plantes
EP2426204A1 (fr) Organogenèse spontanée de nodules dans les plantes
CN108441499A (zh) 雄性育性相关基因ht2925及其应用
EP2534250B1 (fr) Amélioration portant sur le remplissage des grains de blé via la modulation de l'activité de la nadh-glutamate synthase
KR102539626B1 (ko) 식물 수확량 및 이삭 당 낟알 갯수의 조절에 있어서 단백질 nog1의 용도
CN114716522A (zh) Kin10蛋白及其相关生物材料在植物耐盐碱中的应用
TW201522641A (zh) 促進與固氮菌之關連性的植物調控基因
US7179957B1 (en) Method for altering nitrogen or oil content of seeds by down regulating AGL11 expression or activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11752527

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11752527

Country of ref document: EP

Kind code of ref document: A1